<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="publisher-id">International Journal of COPD</journal-id><journal-title-group><journal-title>International Journal of Chronic Obstructive Pulmonary Disease</journal-title></journal-title-group><issn pub-type="ppub">1176-9106</issn><issn pub-type="epub">1178-2005</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29497290</article-id><article-id pub-id-type="pmc">5819581</article-id><article-id pub-id-type="doi">10.2147/COPD.S145440</article-id><article-id pub-id-type="publisher-id">copd-13-617</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Safety and effectiveness of the high-frequency chest wall oscillation vs intrapulmonary percussive ventilation in patients with severe COPD</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Nicolini</surname><given-names>Antonello</given-names></name><xref ref-type="aff" rid="af1-copd-13-617">1</xref><xref ref-type="corresp" rid="c1-copd-13-617"></xref></contrib><contrib contrib-type="author"><name><surname>Grecchi</surname><given-names>Bruna</given-names></name><xref ref-type="aff" rid="af2-copd-13-617">2</xref></contrib><contrib contrib-type="author"><name><surname>Ferrari-Bravo</surname><given-names>Maura</given-names></name><xref ref-type="aff" rid="af3-copd-13-617">3</xref></contrib><contrib contrib-type="author"><name><surname>Barlascini</surname><given-names>Cornelius</given-names></name><xref ref-type="aff" rid="af4-copd-13-617">4</xref></contrib></contrib-group><aff id="af1-copd-13-617">
<label>1</label>Respiratory Diseases Unit, Hospital of Sestri Levante, Sestri Levante, Italy</aff><aff id="af2-copd-13-617">
<label>2</label>Rehabilitation Unit, ASL4 Chiavarese, Chiavari, Italy</aff><aff id="af3-copd-13-617">
<label>3</label>Statistics Unit, ASL4 Chiavarese, Chiavari, Italy</aff><aff id="af4-copd-13-617">
<label>4</label>Health Medicine Unit, Hospital of Sestri Levante, Sestri Levante, Italy</aff><author-notes><corresp id="c1-copd-13-617">Correspondence: Antonello Nicolini, Respiratory Diseases Unit, General Hospital, Via Terzi 43 – 16039, Sestri Levante, Italy, Tel +39 018 532 9145, Fax +39 018 532 9935, Email <email>antonellonicolini@gmail.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>16</day><month>2</month><year>2018</year></pub-date><volume>13</volume><fpage>617</fpage><lpage>625</lpage><permissions><copyright-statement>© 2018 Nicolini et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2018</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title><offsets xml_i="3845" xml_f="3852" txt_i="11" txt_f="18">Purpose</offsets></title><p><offsets xml_i="3863" xml_f="4351" txt_i="19" txt_f="507">Chest physiotherapy is an important tool in the treatment of COPD. Intrapulmonary percussive ventilation (IPV) and high-frequency chest wall oscillation (HFCWO) are techniques designed to create a global percussion of the lung which removes secretions and probably clears the peripheral bronchial tree. We tested the hypothesis that adding IPV or HFCWO to the best pharmacological therapy (PT) may provide additional clinical benefit over chest physiotherapy in patients with severe COPD.</offsets></p></sec><sec><title><offsets xml_i="4373" xml_f="4380" txt_i="509" txt_f="516">Methods</offsets></title><p><offsets xml_i="4391" xml_f="5031" txt_i="517" txt_f="1157">Sixty patients were randomized into three groups (20 patients in each group): IPV group (treated with PT and IPV), PT group with (treated with PT and HFCWO), and control group (treated with PT alone). Primary outcome measures included results on the dyspnea scale (modified Medical Research Council) and Breathlessness, Cough, and Sputum scale (BCSS), as well as an evaluation of daily life activity (COPD Assessment Test [CAT]). Secondary outcome measures were pulmonary function testing, arterial blood gas analysis, and hematological examinations. Moreover, sputum cell counts were performed at the beginning and at the end of the study.</offsets></p></sec><sec><title><offsets xml_i="5053" xml_f="5060" txt_i="1159" txt_f="1166">Results</offsets></title><p><offsets xml_i="5071" xml_f="5983" txt_i="1167" txt_f="2079">Patients in both the IPV group and the HFCWO group showed a significant improvement in the tests of dyspnea and daily life activity evaluations (modified Medical Research Council scale, BCSS, and CAT) compared to the control group, as well as in pulmonary function tests (forced vital capacity, forced expiratory volume in 1 second, forced expiratory volume in 1 second/forced vital capacity%, total lung capacity, residual volume, diffusing lung capacity monoxide, maximal inspiratory pressure, maximal expiratory pressure) and arterial blood gas values. However, in the group comparison analysis for the same variables between IPV group and HFCWO group, we observed a significant improvement in the IPV group maximal inspiratory pressure, maximal expiratory pressure, BCSS, and CAT. Similar results were observed in changes of sputum cytology with reduction of inflammatory cells (neutrophils and macrophages).</offsets></p></sec><sec><title><offsets xml_i="6005" xml_f="6015" txt_i="2081" txt_f="2091">Conclusion</offsets></title><p><offsets xml_i="6026" xml_f="6437" txt_i="2092" txt_f="2503">The two techniques improved daily life activities and lung function in patients with severe COPD. IPV demonstrated a significantly greater effectiveness in improving some pulmonary function tests linked to the small bronchial airways obstruction and respiratory muscle strength and scores on health status assessment scales (BCSS and CAT) as well as a reduction of sputum inflammatory cells compared with HFCWO.</offsets></p></sec></abstract><kwd-group><title>Keywords</title><kwd>severe COPD</kwd><kwd>intrapulmonary percussive ventilation</kwd><kwd>high-frequency chest wall oscillation</kwd><kwd>daily life activity</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title><offsets xml_i="6710" xml_f="6722" txt_i="2512" txt_f="2524">Introduction</offsets></title><p><offsets xml_i="6733" xml_f="6888" txt_i="2525" txt_f="2680">COPD is a lung disease characterized by chronic airflow limitation associated with an enhanced chronic inflammatory response to noxious particles or gases.</offsets><xref rid="b1-copd-13-617" ref-type="bibr"><offsets xml_i="6931" xml_f="6932" txt_i="2680" txt_f="2681">1</offsets></xref><offsets xml_i="6939" xml_f="7152" txt_i="2681" txt_f="2894"> Mucus hypersecretion in COPD has many common causes; some of these include cigarette smoke, acute and chronic viral infection, bacterial infection, and/or inflammatory cell activation of mucin gene transcription.</offsets><xref rid="b2-copd-13-617" ref-type="bibr"><offsets xml_i="7195" xml_f="7196" txt_i="2894" txt_f="2895">2</offsets></xref><offsets xml_i="7203" xml_f="7319" txt_i="2895" txt_f="3011"> The overproduction of mucus and the hypersecretion from increased degranulation is mediated by neutrophil elastase.</offsets><xref rid="b3-copd-13-617" ref-type="bibr"><offsets xml_i="7362" xml_f="7363" txt_i="3011" txt_f="3012">3</offsets></xref><offsets xml_i="7370" xml_f="7605" txt_i="3012" txt_f="3247"> Moreover, there is a difficulty in clearing secretions because of poor ciliary function, distal airway occlusion, and/or an ineffective cough along with reduced peak expiratory flow. This leads to progressive decline in lung function.</offsets><xref rid="b1-copd-13-617" ref-type="bibr"><offsets xml_i="7648" xml_f="7649" txt_i="3247" txt_f="3248">1</offsets></xref><offsets xml_i="7656" xml_f="7657" txt_i="3248" txt_f="3249">,</offsets><xref rid="b4-copd-13-617" ref-type="bibr"><offsets xml_i="7700" xml_f="7701" txt_i="3249" txt_f="3250">4</offsets></xref><offsets xml_i="7708" xml_f="7822" txt_i="3250" txt_f="3364"> Respiratory chest physiotherapy and assisted mucus-clearing techniques are critically important in COPD patients.</offsets><xref rid="b5-copd-13-617" ref-type="bibr"><offsets xml_i="7865" xml_f="7866" txt_i="3364" txt_f="3365">5</offsets></xref><offsets xml_i="7873" xml_f="8033" txt_i="3365" txt_f="3525"> Postural drainage, assisted cough, active cycle of breathing techniques, autogenic drainage, forced expiratory technique, positive expiratory pressure devices,</offsets><xref rid="b6-copd-13-617" ref-type="bibr"><offsets xml_i="8076" xml_f="8077" txt_i="3525" txt_f="3526">6</offsets></xref><offsets xml_i="8084" xml_f="8133" txt_i="3526" txt_f="3575"> oscillatory positive-expiratory pressure devices</offsets><xref rid="b7-copd-13-617" ref-type="bibr"><offsets xml_i="8176" xml_f="8177" txt_i="3575" txt_f="3576">7</offsets></xref><offsets xml_i="8184" xml_f="8251" txt_i="3576" txt_f="3643"> and, more recently, high-frequency chest wall oscillation (HFCWO),</offsets><xref rid="b8-copd-13-617" ref-type="bibr"><offsets xml_i="8294" xml_f="8295" txt_i="3643" txt_f="3644">8</offsets></xref><offsets xml_i="8302" xml_f="8351" txt_i="3644" txt_f="3693"> intermittent positive pressure breathing (IPPB),</offsets><xref rid="b9-copd-13-617" ref-type="bibr"><offsets xml_i="8394" xml_f="8395" txt_i="3693" txt_f="3694">9</offsets></xref><offsets xml_i="8402" xml_f="8447" txt_i="3694" txt_f="3739"> intrapulmonary percussive ventilation (IPV),</offsets><xref rid="b10-copd-13-617" ref-type="bibr"><offsets xml_i="8491" xml_f="8493" txt_i="3739" txt_f="3741">10</offsets></xref><offsets xml_i="8500" xml_f="8543" txt_i="3741" txt_f="3784"> and temporary positive expiratory pressure</offsets><xref rid="b11-copd-13-617" ref-type="bibr"><offsets xml_i="8587" xml_f="8589" txt_i="3784" txt_f="3786">11</offsets></xref><offsets xml_i="8596" xml_f="8597" txt_i="3786" txt_f="3787">,</offsets><xref rid="b12-copd-13-617" ref-type="bibr"><offsets xml_i="8641" xml_f="8643" txt_i="3787" txt_f="3789">12</offsets></xref><offsets xml_i="8650" xml_f="8828" txt_i="3789" txt_f="3967"> are the techniques that have been proposed over the years for secretion management. The efficacy of these techniques during acute exacerbation or stable disease remains unclear.</offsets><xref rid="b13-copd-13-617" ref-type="bibr"><offsets xml_i="8872" xml_f="8874" txt_i="3967" txt_f="3969">13</offsets></xref><offsets xml_i="8881" xml_f="8895" txt_i="3969" txt_f="3983"> Osadnik et al</offsets><xref rid="b13-copd-13-617" ref-type="bibr"><offsets xml_i="8939" xml_f="8941" txt_i="3983" txt_f="3985">13</offsets></xref><offsets xml_i="8948" xml_f="9754" txt_i="3985" txt_f="4791"> reviewed twenty-eight studies including 907 participants in a meta-analysis; however, the quality was considered poor due to inadequate blinding and allocation procedure and the results were limited by heterogeneity of outcome measurement and inadequacy of data. The conclusions were that airway clearance techniques are safe for individuals with COPD, but the benefits are less clear. IPV was designed to promote mobilization of bronchial secretions and improve efficiency and distribution of ventilation, providing intrathoracic percussion and vibration and an alternative system for the delivery of the positive pressure to the lungs. HFCWO involves an inflatable jacket that is attached to a pulse generator by hoses that mechanically enable the equipment to perform at variable frequencies (5–25 Hz).</offsets><xref rid="b14-copd-13-617" ref-type="bibr"><offsets xml_i="9798" xml_f="9800" txt_i="4791" txt_f="4793">14</offsets></xref><offsets xml_i="9807" xml_f="10013" txt_i="4793" txt_f="4999"> The generator sends air through the hose, which causes the vest to inflate and deflate rapidly. The vibrations not only separate mucus from the airway walls but also help move it up into the large airways.</offsets><xref rid="b15-copd-13-617" ref-type="bibr"><offsets xml_i="10057" xml_f="10059" txt_i="4999" txt_f="5001">15</offsets></xref><offsets xml_i="10066" xml_f="10325" txt_i="5001" txt_f="5260"> Regarding these two different techniques, we conducted a randomized controlled study aimed at comparing their short-term effects in severe to very severe (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 3–4, assessment C–D) COPD patients.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="10366" xml_f="10373" txt_i="5262" txt_f="5269">Methods</offsets></title><p><offsets xml_i="10384" xml_f="10838" txt_i="5270" txt_f="5724">The study was carried out at the Pulmonary Rehabilitation Center of the Respiratory Diseases Department of General Hospital of Sestri Levante from April 2013 to December 2013 and was approved by Local Ethics Committee. Written informed consent was obtained from all participants and procedures were conducted according to the Declaration of Helsinki. The study was registered with the Chinese Clinical Trial Registry, with the number ChiCTR-TRC-12002133.</offsets></p><sec sec-type="subjects"><title><offsets xml_i="10874" xml_f="10882" txt_i="5725" txt_f="5733">Patients</offsets></title><p><offsets xml_i="10893" xml_f="11861" txt_i="5734" txt_f="6696">Seventy nine patients with stable severe to very severe COPD admitted to The Rehabilitation outpatient clinic were recruited. Inclusion criteria were as follows: age at least 35 years, presence of chronic bronchitis and airway obstruction on spirometry (GOLD stage 3–4, C–D assessment), bronchial hypersecretion (daily sputum &gt;20 mL for at least 2 consecutive days), and effective cough (peak expiratory cough flow &gt;360 L/min). Exclusion criteria were the following: exacerbation of COPD or hospitalization for COPD within 8 weeks prior to recruitment, history of bronchial asthma, predominant bronchiectasis, presence of tracheostomy, mechanical ventilation, recent pneumothorax, severe abnormalities of sensory, severe cardiac arrhythmias, hemodynamic instability, and chest radiograph changes. The drop-out criteria were the inability to comply to study procedures or the lack of a written informed consent and the occurrence of any of the exclusion criteria.</offsets></p></sec><sec><title><offsets xml_i="11883" xml_f="11891" txt_i="6698" txt_f="6706">Protocol</offsets></title><p><offsets xml_i="11902" xml_f="12233" txt_i="6707" txt_f="7038">This was a 4-week parallel randomized controlled study comparing IPV, HFCWO, and the best medical therapy. The aim of the study was to verify the effectiveness and the patients’ preference regarding the two methods. Patients who met inclusion criteria were enrolled and randomized into three groups as depicted in the flowchart in </offsets><xref ref-type="fig" rid="f1-copd-13-617"><offsets xml_i="12275" xml_f="12283" txt_i="7038" txt_f="7046">Figure 1</offsets></xref><offsets xml_i="12290" xml_f="12412" txt_i="7046" txt_f="7168">. A randomization schedule was generated by an independent statistician using an online random permutation generator from </offsets><ext-link ext-link-type="uri" xlink:href="http://www.randomization.com"><offsets xml_i="12484" xml_f="12512" txt_i="7168" txt_f="7196">http://www.randomization.com</offsets></ext-link><offsets xml_i="12523" xml_f="12713" txt_i="7196" txt_f="7386">. The randomization assignments were provided to the physicians in sealed envelopes. The investigators who carried out the study data analysis were blinded to patients’ treatment assignment.</offsets></p></sec><sec><title><offsets xml_i="12735" xml_f="12755" txt_i="7388" txt_f="7408">Treatments protocols</offsets></title><p><offsets xml_i="12766" xml_f="12880" txt_i="7409" txt_f="7523">IPV was provided by a respiratory physiotherapist using a percussive ventilator (IPV Impulsator, Percussionaire) (</offsets><xref ref-type="fig" rid="f2-copd-13-617"><offsets xml_i="12922" xml_f="12931" txt_i="7523" txt_f="7532">Figure 2A</offsets></xref><offsets xml_i="12938" xml_f="13181" txt_i="7532" txt_f="7775">). The impact of calibration (adjustment of inspiratory to expiratory ratio), percussion (frequency of delivered breaths), and source pressure (amplitude/pressure rise of delivered breaths) was adjusted using some suggested setting parameters.</offsets><xref rid="b10-copd-13-617" ref-type="bibr"><offsets xml_i="13225" xml_f="13227" txt_i="7775" txt_f="7777">10</offsets></xref><offsets xml_i="13234" xml_f="13484" txt_i="7777" txt_f="8027"> Each IPV session lasted fifteen minutes and was performed twice a day (morning and afternoon). HFCWO was delivered by a respiratory physiotherapist using a percussive vest (The Vest Airway Clearance System Model 205, Hill-Rom, Batesville, IN, USA) (</offsets><xref ref-type="fig" rid="f2-copd-13-617"><offsets xml_i="13526" xml_f="13535" txt_i="8027" txt_f="8036">Figure 2B</offsets></xref><offsets xml_i="13542" xml_f="13646" txt_i="8036" txt_f="8140">) at 13–15 Hz oscillating frequency, based on patient’s tolerance, and at a pressure setting of 2–5 cm H</offsets><sub><offsets xml_i="13651" xml_f="13652" txt_i="8140" txt_f="8141">2</offsets></sub><offsets xml_i="13658" xml_f="13704" txt_i="8141" txt_f="8187">O to achieve a tight but comfortable snug fit.</offsets><xref rid="b14-copd-13-617" ref-type="bibr"><offsets xml_i="13748" xml_f="13750" txt_i="8187" txt_f="8189">14</offsets></xref><offsets xml_i="13757" xml_f="13758" txt_i="8189" txt_f="8190">,</offsets><xref rid="b15-copd-13-617" ref-type="bibr"><offsets xml_i="13802" xml_f="13804" txt_i="8190" txt_f="8192">15</offsets></xref><offsets xml_i="13811" xml_f="14153" txt_i="8192" txt_f="8534"> Each HFCWO session lasted 20 minutes and was performed twice a day (morning and afternoon). Subjects for both procedures were kept in a sitting position. The duration of the treatments for each group was 2 weeks. The patients were evaluated one week before the start of airway clearance treatment and one week after the end of the treatment.</offsets></p></sec><sec><title><offsets xml_i="14175" xml_f="14200" txt_i="8536" txt_f="8561">Measurements and outcomes</offsets></title><p><offsets xml_i="14211" xml_f="14481" txt_i="8562" txt_f="8832">The primary outcomes of the study were the assessment of changes in dyspnea and quality of life as well as daily life activity and healthy status assessment. The secondary outcomes were changes in respiratory function testing, hematological tests, and sputum cell count.</offsets></p><p><offsets xml_i="14488" xml_f="14573" txt_i="8833" txt_f="8918">Dyspnea was measured with the Modified Medical Research Council (mMRC) Dyspnea Scale;</offsets><xref rid="b16-copd-13-617" ref-type="bibr"><offsets xml_i="14617" xml_f="14619" txt_i="8918" txt_f="8920">16</offsets></xref><offsets xml_i="14626" xml_f="14713" txt_i="8920" txt_f="9007"> cough and sputum was assessed with the Breathlessness, Cough, and Sputum Scale (BCSS);</offsets><xref rid="b17-copd-13-617" ref-type="bibr"><offsets xml_i="14757" xml_f="14759" txt_i="9007" txt_f="9009">17</offsets></xref><offsets xml_i="14766" xml_f="14767" txt_i="9009" txt_f="9010">,</offsets><xref rid="b18-copd-13-617" ref-type="bibr"><offsets xml_i="14811" xml_f="14813" txt_i="9010" txt_f="9012">18</offsets></xref><offsets xml_i="14820" xml_f="14917" txt_i="9012" txt_f="9109"> daily life activity and healthy status assessment were measured with COPD Assessment Test (CAT).</offsets><xref rid="b19-copd-13-617" ref-type="bibr"><offsets xml_i="14961" xml_f="14963" txt_i="9109" txt_f="9111">19</offsets></xref><offsets xml_i="14970" xml_f="14971" txt_i="9111" txt_f="9112">,</offsets><xref rid="b20-copd-13-617" ref-type="bibr"><offsets xml_i="15015" xml_f="15017" txt_i="9112" txt_f="9114">20</offsets></xref><offsets xml_i="15024" xml_f="15129" txt_i="9114" txt_f="9219"> Pulmonary function testing including forced vital capacity (FVC), forced expiratory volume 1 second (FEV</offsets><sub><offsets xml_i="15134" xml_f="15135" txt_i="9219" txt_f="9220">1</offsets></sub><offsets xml_i="15141" xml_f="15147" txt_i="9220" txt_f="9226">), FEV</offsets><sub><offsets xml_i="15152" xml_f="15153" txt_i="9226" txt_f="9227">1</offsets></sub><offsets xml_i="15159" xml_f="15391" txt_i="9227" txt_f="9459">/FVC%, total lung capacity (TLC), residual volume (RV), diffusing lung capacity monoxide (DLCO), maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), peak cough expiratory flow, and arterial blood gas analysis (Pao</offsets><sub><offsets xml_i="15396" xml_f="15397" txt_i="9459" txt_f="9460">2</offsets></sub><offsets xml_i="15403" xml_f="15409" txt_i="9460" txt_f="9466">, Paco</offsets><sub><offsets xml_i="15414" xml_f="15415" txt_i="9466" txt_f="9467">2</offsets></sub><offsets xml_i="15421" xml_f="15570" txt_i="9467" txt_f="9616">, pH) were performed with a computerized body plethysmography (VMAX 20 PFT Sensor Medics, Yorba Linda, CA, USA), according to the ATS/ERS Guidelines.</offsets><xref rid="b21-copd-13-617" ref-type="bibr"><offsets xml_i="15614" xml_f="15616" txt_i="9616" txt_f="9618">21</offsets></xref><offsets xml_i="15623" xml_f="15624" txt_i="9618" txt_f="9619">–</offsets><xref rid="b23-copd-13-617" ref-type="bibr"><offsets xml_i="15668" xml_f="15670" txt_i="9619" txt_f="9621">23</offsets></xref><offsets xml_i="15677" xml_f="15942" txt_i="9621" txt_f="9886"> Inspiratory muscle strength was assessed by measuring the MIP at RV. Expiratory muscle strength was assessed by measuring the MEP at TLC. The value obtained from the best of at least three effort was used. All the measurements were obtained in an upright position.</offsets><xref rid="b24-copd-13-617" ref-type="bibr"><offsets xml_i="15986" xml_f="15988" txt_i="9886" txt_f="9888">24</offsets></xref><offsets xml_i="15995" xml_f="15996" txt_i="9888" txt_f="9889">,</offsets><xref rid="b25-copd-13-617" ref-type="bibr"><offsets xml_i="16040" xml_f="16042" txt_i="9889" txt_f="9891">25</offsets></xref><offsets xml_i="16049" xml_f="16122" txt_i="9891" txt_f="9964"> Diagnosis and severity of COPD were confirmed using the GOLD Guidelines.</offsets><xref rid="b26-copd-13-617" ref-type="bibr"><offsets xml_i="16166" xml_f="16168" txt_i="9964" txt_f="9966">26</offsets></xref></p><p><offsets xml_i="16182" xml_f="16779" txt_i="9967" txt_f="10564">Sputum collection was made on the day the treatment was started and on the day of the last treatment. The patients were instructed by the physiotherapists or by the nurses to expectorate into the sputum cups during the entire duration of the treatment and to continue expectorating if the patient felt the need to cough. Sputum induction was performed using a previously described method. Briefly, the procedure was started 10 minutes after the administration of 200 µg of inhaled salbutamol using a 3% hypertonic saline solution. Sputum samples were processed within 2 hours after the collection.</offsets><xref rid="b27-copd-13-617" ref-type="bibr"><offsets xml_i="16823" xml_f="16825" txt_i="10564" txt_f="10566">27</offsets></xref><offsets xml_i="16832" xml_f="16833" txt_i="10566" txt_f="10567">–</offsets><xref rid="b29-copd-13-617" ref-type="bibr"><offsets xml_i="16877" xml_f="16879" txt_i="10567" txt_f="10569">29</offsets></xref><offsets xml_i="16886" xml_f="17167" txt_i="10569" txt_f="10850"> Sputum samples were considered for analysis if they contained expectorated material with cellular viability greater than 50%, had contamination with oropharyngeal squamous cells at a level lower than 20%, and were of sufficient quantity to enable differential counts of 400 cells.</offsets><xref rid="b28-copd-13-617" ref-type="bibr"><offsets xml_i="17211" xml_f="17213" txt_i="10850" txt_f="10852">28</offsets></xref><offsets xml_i="17220" xml_f="17221" txt_i="10852" txt_f="10853">,</offsets><xref rid="b29-copd-13-617" ref-type="bibr"><offsets xml_i="17265" xml_f="17267" txt_i="10853" txt_f="10855">29</offsets></xref><offsets xml_i="17274" xml_f="17630" txt_i="10855" txt_f="11211"> Finally at the end of treatment, subjects treated with IPV or HFCWO were asked to complete a written questionnaire to rate comfort, effectiveness, ease of use, and convenience of the respective procedures. The answers were given using a 5-point Likert-type scale. The possible responses were extremely =4, very =3, somewhat =2, not very =1, not at all =0.</offsets><xref rid="b30-copd-13-617" ref-type="bibr"><offsets xml_i="17674" xml_f="17676" txt_i="11211" txt_f="11213">30</offsets></xref></p></sec></sec><sec><title><offsets xml_i="17711" xml_f="17731" txt_i="11216" txt_f="11236">Statistical analysis</offsets></title><p><offsets xml_i="17742" xml_f="18187" txt_i="11237" txt_f="11682">Clinical data were expressed as counts and mean and SD. We calculated the difference between the two treatments (HFCWO and IPV) and control group using univariate regression analysis. Subsequently, the difference between the two treatments (HFCWO and IPV) was analyzed using univariate regression analysis. In addition, a Wilcoxon test was applied to the patients’ preference rankings. Differences were considered statistically significant when </offsets><italic><offsets xml_i="18195" xml_f="18196" txt_i="11682" txt_f="11683">p</offsets></italic><offsets xml_i="18205" xml_f="18295" txt_i="11683" txt_f="11773">≤0.05. Data analysis was performed using the statistics software R-Project version 2.13.2.</offsets></p></sec><sec sec-type="results"><title><offsets xml_i="18336" xml_f="18343" txt_i="11775" txt_f="11782">Results</offsets></title><p><offsets xml_i="18354" xml_f="18649" txt_i="11783" txt_f="12078">Sixty-three patients were recruited. Three patients withdrew prior to completing the study. Two patients belonged to the control group and one patient belonged to HFCWO group. Sixty patients completed the study. All patients had similar characteristics. The patient characteristics are given in </offsets><xref ref-type="table" rid="t1-copd-13-617"><offsets xml_i="18693" xml_f="18700" txt_i="12078" txt_f="12085">Table 1</offsets></xref><offsets xml_i="18707" xml_f="18803" txt_i="12085" txt_f="12181">. No changes in respiratory therapy or COPD exacerbations were observed during the study period.</offsets></p><sec><title><offsets xml_i="18819" xml_f="18835" txt_i="12182" txt_f="12198">Primary outcomes</offsets></title><p><offsets xml_i="18846" xml_f="19114" txt_i="12199" txt_f="12467">Patients in both the IPV group and the HFCWO group showed a significant improvement in the tests of dyspnea and daily life and health status assessment (mMRC, BCSS, and CAT) compared to those in the control group. Moreover, IPV patients showed an improvement in BCSS (</offsets><italic><offsets xml_i="19122" xml_f="19123" txt_i="12467" txt_f="12468">p</offsets></italic><offsets xml_i="19132" xml_f="19152" txt_i="12468" txt_f="12485">&lt;0.001) and CAT (</offsets><italic><offsets xml_i="19160" xml_f="19161" txt_i="12485" txt_f="12486">p</offsets></italic><offsets xml_i="19170" xml_f="19241" txt_i="12486" txt_f="12554">&lt;0.02) scores in comparison with HFCWO. The results are reported in </offsets><xref ref-type="table" rid="t2-copd-13-617"><offsets xml_i="19285" xml_f="19292" txt_i="12554" txt_f="12561">Table 2</offsets></xref><offsets xml_i="19299" xml_f="19351" txt_i="12561" txt_f="12613">. The box-plots of BCSS and CAT scores are shown in </offsets><xref ref-type="fig" rid="f3-copd-13-617"><offsets xml_i="19393" xml_f="19401" txt_i="12613" txt_f="12621">Figure 3</offsets></xref><offsets xml_i="19408" xml_f="19409" txt_i="12621" txt_f="12622">.</offsets></p></sec><sec><title><offsets xml_i="19431" xml_f="19449" txt_i="12624" txt_f="12642">Secondary outcomes</offsets></title><p><offsets xml_i="19460" xml_f="19634" txt_i="12643" txt_f="12817">Both the techniques improved several parameters in the patient groups compared to control group (white blood cells, neutrophils, and lymphocytes; C-reactive protein; FVC; FEV</offsets><sub><offsets xml_i="19639" xml_f="19640" txt_i="12817" txt_f="12818">1</offsets></sub><offsets xml_i="19646" xml_f="19651" txt_i="12818" txt_f="12823">; FEV</offsets><sub><offsets xml_i="19656" xml_f="19657" txt_i="12823" txt_f="12824">1</offsets></sub><offsets xml_i="19663" xml_f="19707" txt_i="12824" txt_f="12868">/FVC%; TLC; RV; RV/TLC%; DLCO; MIP; MEP; PaO</offsets><sub><offsets xml_i="19712" xml_f="19713" txt_i="12868" txt_f="12869">2</offsets></sub><offsets xml_i="19719" xml_f="19725" txt_i="12869" txt_f="12875">; PaCO</offsets><sub><offsets xml_i="19730" xml_f="19731" txt_i="12875" txt_f="12876">2</offsets></sub><offsets xml_i="19737" xml_f="19920" txt_i="12876" txt_f="13059">; and pH). However, in the group comparison analysis for the same variables between IPV group and HFCWO group, we observed a significant improvement in the IPV group in TLC and TLC% (</offsets><italic><offsets xml_i="19928" xml_f="19929" txt_i="13059" txt_f="13060">p</offsets></italic><offsets xml_i="19938" xml_f="19961" txt_i="13060" txt_f="13080">&lt;0.03), RV and RV% (</offsets><italic><offsets xml_i="19969" xml_f="19970" txt_i="13080" txt_f="13081">p</offsets></italic><offsets xml_i="19979" xml_f="20014" txt_i="13081" txt_f="13113">&lt;0.04), and DLCO, MIP, and MEP (</offsets><italic><offsets xml_i="20022" xml_f="20023" txt_i="13113" txt_f="13114">p</offsets></italic><offsets xml_i="20032" xml_f="20075" txt_i="13114" txt_f="13154">&lt;0.01). These results are summarized in </offsets><xref ref-type="table" rid="t3-copd-13-617"><offsets xml_i="20119" xml_f="20126" txt_i="13154" txt_f="13161">Table 3</offsets></xref><offsets xml_i="20133" xml_f="20134" txt_i="13161" txt_f="13162">.</offsets></p></sec><sec><title><offsets xml_i="20156" xml_f="20170" txt_i="13164" txt_f="13178">Sputum changes</offsets></title><p><offsets xml_i="20181" xml_f="20510" txt_i="13179" txt_f="13508">A significant change in total cell count and neutrophil, lymphocyte, and macrophage counts in sputum samples were observed in the patients receiving either of the two treatments (IPV and HFCWO) compared to control group. Only a slight significant change in neutrophil count was observed in the IPV group compared to HFCWO group (</offsets><italic><offsets xml_i="20518" xml_f="20519" txt_i="13508" txt_f="13509">p</offsets></italic><offsets xml_i="20528" xml_f="20610" txt_i="13509" txt_f="13588">&lt;0.05). All the results of the sputum cells count measurements are reported in </offsets><xref ref-type="table" rid="t4-copd-13-617"><offsets xml_i="20654" xml_f="20661" txt_i="13588" txt_f="13595">Table 4</offsets></xref><offsets xml_i="20668" xml_f="20669" txt_i="13595" txt_f="13596">.</offsets></p></sec><sec><title><offsets xml_i="20691" xml_f="20727" txt_i="13598" txt_f="13634">Measurement of patient acceptability</offsets></title><p><offsets xml_i="20738" xml_f="20960" txt_i="13635" txt_f="13857">The 40 patients who finished the study (20 in each group) completed the questionnaire and rated the comfort, efficacy, ease of use, and convenience. A similar ranking was expressed by the patients for both the techniques. </offsets><xref ref-type="table" rid="t5-copd-13-617"><offsets xml_i="21004" xml_f="21011" txt_i="13857" txt_f="13864">Table 5</offsets></xref><offsets xml_i="21018" xml_f="21062" txt_i="13864" txt_f="13908"> shows the mean ± SD rating and the ranking.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="21112" xml_f="21122" txt_i="13911" txt_f="13921">Discussion</offsets></title><p><offsets xml_i="21133" xml_f="21634" txt_i="13922" txt_f="14423">Techniques for increasing the normal airway clearance are a vital component of therapy. Mechanisms which can be performed without an assistant or without being dependent on a caregiver provide greater control as well as patient satisfaction and are considered important in many areas of medicine (eg, diabetes). Techniques which can be used in a majority of adolescents and adults with pulmonary disease that lead to an increase in adherence with daily therapy have been developed in the recent years.</offsets><xref rid="b31-copd-13-617" ref-type="bibr"><offsets xml_i="21678" xml_f="21680" txt_i="14423" txt_f="14425">31</offsets></xref><offsets xml_i="21687" xml_f="22174" txt_i="14425" txt_f="14912"> Thus, methods such as the application of positive expiratory pressure and use of flutter valves or high-frequency chest compression vests have been evaluated with good results in cystic fibrosis patients; these techniques have not been well studied in the COPD patient population. There are a few trials that have studied chest physiotherapy or directed coughing techniques in COPD patients. These trials have shown some improvements in mucus clearance, but no changes in lung function.</offsets><xref rid="b2-copd-13-617" ref-type="bibr"><offsets xml_i="22217" xml_f="22218" txt_i="14912" txt_f="14913">2</offsets></xref><offsets xml_i="22225" xml_f="22226" txt_i="14913" txt_f="14914">,</offsets><xref rid="b32-copd-13-617" ref-type="bibr"><offsets xml_i="22270" xml_f="22272" txt_i="14914" txt_f="14916">32</offsets></xref><offsets xml_i="22279" xml_f="22280" txt_i="14916" txt_f="14917">,</offsets><xref rid="b33-copd-13-617" ref-type="bibr"><offsets xml_i="22324" xml_f="22326" txt_i="14917" txt_f="14919">33</offsets></xref><offsets xml_i="22333" xml_f="22453" txt_i="14919" txt_f="15039"> Several studies have been published regarding the two instruments, both in bronchiectasis and cystic fibrosis patients,</offsets><xref rid="b8-copd-13-617" ref-type="bibr"><offsets xml_i="22496" xml_f="22497" txt_i="15039" txt_f="15040">8</offsets></xref><offsets xml_i="22504" xml_f="22505" txt_i="15040" txt_f="15041">,</offsets><xref rid="b9-copd-13-617" ref-type="bibr"><offsets xml_i="22548" xml_f="22549" txt_i="15041" txt_f="15042">9</offsets></xref><offsets xml_i="22556" xml_f="22557" txt_i="15042" txt_f="15043">,</offsets><xref rid="b30-copd-13-617" ref-type="bibr"><offsets xml_i="22601" xml_f="22603" txt_i="15043" txt_f="15045">30</offsets></xref><offsets xml_i="22610" xml_f="22611" txt_i="15045" txt_f="15046">,</offsets><xref rid="b34-copd-13-617" ref-type="bibr"><offsets xml_i="22655" xml_f="22657" txt_i="15046" txt_f="15048">34</offsets></xref><offsets xml_i="22664" xml_f="22665" txt_i="15048" txt_f="15049">–</offsets><xref rid="b49-copd-13-617" ref-type="bibr"><offsets xml_i="22709" xml_f="22711" txt_i="15049" txt_f="15051">49</offsets></xref><offsets xml_i="22718" xml_f="22739" txt_i="15051" txt_f="15072"> or in COPD patients,</offsets><xref rid="b49-copd-13-617" ref-type="bibr"><offsets xml_i="22783" xml_f="22785" txt_i="15072" txt_f="15074">49</offsets></xref><offsets xml_i="22792" xml_f="22793" txt_i="15074" txt_f="15075">–</offsets><xref rid="b60-copd-13-617" ref-type="bibr"><offsets xml_i="22837" xml_f="22839" txt_i="15075" txt_f="15077">60</offsets></xref><offsets xml_i="22846" xml_f="22891" txt_i="15077" txt_f="15122"> but only two studies compared IPV and HFCWO.</offsets><xref rid="b30-copd-13-617" ref-type="bibr"><offsets xml_i="22935" xml_f="22937" txt_i="15122" txt_f="15124">30</offsets></xref><offsets xml_i="22944" xml_f="22945" txt_i="15124" txt_f="15125">,</offsets><xref rid="b61-copd-13-617" ref-type="bibr"><offsets xml_i="22989" xml_f="22991" txt_i="15125" txt_f="15127">61</offsets></xref><offsets xml_i="22998" xml_f="23079" txt_i="15127" txt_f="15208"> In the previously published studies, IPV reduced the incidence of exacerbations,</offsets><xref rid="b49-copd-13-617" ref-type="bibr"><offsets xml_i="23123" xml_f="23125" txt_i="15208" txt_f="15210">49</offsets></xref><offsets xml_i="23132" xml_f="23133" txt_i="15210" txt_f="15211">,</offsets><xref rid="b53-copd-13-617" ref-type="bibr"><offsets xml_i="23177" xml_f="23179" txt_i="15211" txt_f="15213">53</offsets></xref><offsets xml_i="23186" xml_f="23222" txt_i="15213" txt_f="15249"> improved arterial blood gas values,</offsets><xref rid="b51-copd-13-617" ref-type="bibr"><offsets xml_i="23266" xml_f="23268" txt_i="15249" txt_f="15251">51</offsets></xref><offsets xml_i="23275" xml_f="23276" txt_i="15251" txt_f="15252">,</offsets><xref rid="b53-copd-13-617" ref-type="bibr"><offsets xml_i="23320" xml_f="23322" txt_i="15252" txt_f="15254">53</offsets></xref><offsets xml_i="23329" xml_f="23330" txt_i="15254" txt_f="15255">,</offsets><xref rid="b54-copd-13-617" ref-type="bibr"><offsets xml_i="23374" xml_f="23376" txt_i="15255" txt_f="15257">54</offsets></xref><offsets xml_i="23383" xml_f="23384" txt_i="15257" txt_f="15258">,</offsets><xref rid="b57-copd-13-617" ref-type="bibr"><offsets xml_i="23428" xml_f="23430" txt_i="15258" txt_f="15260">57</offsets></xref><offsets xml_i="23437" xml_f="23469" txt_i="15260" txt_f="15292"> reduced diaphragmatic workload,</offsets><xref rid="b50-copd-13-617" ref-type="bibr"><offsets xml_i="23513" xml_f="23515" txt_i="15292" txt_f="15294">50</offsets></xref><offsets xml_i="23522" xml_f="23544" txt_i="15294" txt_f="15316"> and improved dyspnea,</offsets><xref rid="b34-copd-13-617" ref-type="bibr"><offsets xml_i="23588" xml_f="23590" txt_i="15316" txt_f="15318">34</offsets></xref><offsets xml_i="23597" xml_f="23598" txt_i="15318" txt_f="15319">,</offsets><xref rid="b51-copd-13-617" ref-type="bibr"><offsets xml_i="23642" xml_f="23644" txt_i="15319" txt_f="15321">51</offsets></xref><offsets xml_i="23651" xml_f="23691" txt_i="15321" txt_f="15361"> some respiratory functional parameters,</offsets><xref rid="b34-copd-13-617" ref-type="bibr"><offsets xml_i="23735" xml_f="23737" txt_i="15361" txt_f="15363">34</offsets></xref><offsets xml_i="23744" xml_f="23745" txt_i="15363" txt_f="15364">,</offsets><xref rid="b52-copd-13-617" ref-type="bibr"><offsets xml_i="23789" xml_f="23791" txt_i="15364" txt_f="15366">52</offsets></xref><offsets xml_i="23798" xml_f="23799" txt_i="15366" txt_f="15367">,</offsets><xref rid="b57-copd-13-617" ref-type="bibr"><offsets xml_i="23843" xml_f="23845" txt_i="15367" txt_f="15369">57</offsets></xref><offsets xml_i="23852" xml_f="23871" txt_i="15369" txt_f="15388"> and sputum volume.</offsets><xref rid="b30-copd-13-617" ref-type="bibr"><offsets xml_i="23915" xml_f="23917" txt_i="15388" txt_f="15390">30</offsets></xref><offsets xml_i="23924" xml_f="24027" txt_i="15390" txt_f="15493"> HFCWO showed the following findings: improvement of wet weight sputum or greater sputum expectoration,</offsets><xref rid="b8-copd-13-617" ref-type="bibr"><offsets xml_i="24070" xml_f="24071" txt_i="15493" txt_f="15494">8</offsets></xref><offsets xml_i="24078" xml_f="24079" txt_i="15494" txt_f="15495">,</offsets><xref rid="b40-copd-13-617" ref-type="bibr"><offsets xml_i="24123" xml_f="24125" txt_i="15495" txt_f="15497">40</offsets></xref><offsets xml_i="24132" xml_f="24133" txt_i="15497" txt_f="15498">,</offsets><xref rid="b43-copd-13-617" ref-type="bibr"><offsets xml_i="24177" xml_f="24179" txt_i="15498" txt_f="15500">43</offsets></xref><offsets xml_i="24186" xml_f="24221" txt_i="15500" txt_f="15535"> reduction of dyspnea (Borg score),</offsets><xref rid="b44-copd-13-617" ref-type="bibr"><offsets xml_i="24265" xml_f="24267" txt_i="15535" txt_f="15537">44</offsets></xref><offsets xml_i="24274" xml_f="24275" txt_i="15537" txt_f="15538">,</offsets><xref rid="b59-copd-13-617" ref-type="bibr"><offsets xml_i="24319" xml_f="24321" txt_i="15538" txt_f="15540">59</offsets></xref><offsets xml_i="24328" xml_f="24433" txt_i="15540" txt_f="15645"> improvement of healthy scores (CAT and BCSS) and quality of life (St Georges Respiratory Questionnaire),</offsets><xref rid="b14-copd-13-617" ref-type="bibr"><offsets xml_i="24477" xml_f="24479" txt_i="15645" txt_f="15647">14</offsets></xref><offsets xml_i="24486" xml_f="24487" txt_i="15647" txt_f="15648">,</offsets><xref rid="b60-copd-13-617" ref-type="bibr"><offsets xml_i="24531" xml_f="24533" txt_i="15648" txt_f="15650">60</offsets></xref><offsets xml_i="24540" xml_f="24596" txt_i="15650" txt_f="15706"> improvement in ventilation distribution and gas mixing,</offsets><xref rid="b41-copd-13-617" ref-type="bibr"><offsets xml_i="24640" xml_f="24642" txt_i="15706" txt_f="15708">41</offsets></xref><offsets xml_i="24649" xml_f="24710" txt_i="15708" txt_f="15769"> improvement of respiratory function parameters (FVC, and FEV</offsets><sub><offsets xml_i="24715" xml_f="24716" txt_i="15769" txt_f="15770">1</offsets></sub><offsets xml_i="24722" xml_f="24724" txt_i="15770" txt_f="15772">),</offsets><xref rid="b8-copd-13-617" ref-type="bibr"><offsets xml_i="24767" xml_f="24768" txt_i="15772" txt_f="15773">8</offsets></xref><offsets xml_i="24775" xml_f="24776" txt_i="15773" txt_f="15774">,</offsets><xref rid="b14-copd-13-617" ref-type="bibr"><offsets xml_i="24820" xml_f="24822" txt_i="15774" txt_f="15776">14</offsets></xref><offsets xml_i="24829" xml_f="24830" txt_i="15776" txt_f="15777">,</offsets><xref rid="b15-copd-13-617" ref-type="bibr"><offsets xml_i="24874" xml_f="24876" txt_i="15777" txt_f="15779">15</offsets></xref><offsets xml_i="24883" xml_f="24884" txt_i="15779" txt_f="15780">,</offsets><xref rid="b41-copd-13-617" ref-type="bibr"><offsets xml_i="24928" xml_f="24930" txt_i="15780" txt_f="15782">41</offsets></xref><offsets xml_i="24937" xml_f="24972" txt_i="15782" txt_f="15817"> and changes in sputum cell counts.</offsets><xref rid="b14-copd-13-617" ref-type="bibr"><offsets xml_i="25016" xml_f="25018" txt_i="15817" txt_f="15819">14</offsets></xref><offsets xml_i="25025" xml_f="25054" txt_i="15819" txt_f="15848"> The study by Varekojis et al</offsets><xref rid="b30-copd-13-617" ref-type="bibr"><offsets xml_i="25098" xml_f="25100" txt_i="15848" txt_f="15850">30</offsets></xref><offsets xml_i="25107" xml_f="25725" txt_i="15850" txt_f="16468"> has compared the therapeutic effectiveness and preference of postural drainage and percussion with IPV and HFCWO. Effectiveness was evaluated by measuring the weight of the wet and dry sputum obtained with each method as well as based on the results of preference obtained by using a Likert-type scale. The wet sputum weight differed significantly and was greater in the IPV group. The second study compared IPV and HFCWO in pediatric tracheostomized patients. IPV was more effective than HFCWO in reducing lower respiratory tract infections, steroid and bronchodilator use, as well as the number of hospitalizations.</offsets><xref rid="b61-copd-13-617" ref-type="bibr"><offsets xml_i="25769" xml_f="25771" txt_i="16468" txt_f="16470">61</offsets></xref><offsets xml_i="25778" xml_f="26044" txt_i="16470" txt_f="16736"> Our study has evaluated short-term effects of the two techniques on patients with severe to very severe COPD. We have found a significant improvement in the dyspnea, scores on health status assessment scales, as well as in pulmonary function tests and gas exchange.</offsets></p><p><offsets xml_i="26051" xml_f="26781" txt_i="16737" txt_f="17467">Besides, in the group comparison analysis for the same variables between the IPV group and the HFCWO group, a significant improvement in the IPV group in TLC, RV, DLCO, MIP, MEP, BCSS, and CAT was observed. The latter data may suggest that IPV can also act on small bronchial airway obstruction and improve alveolar ventilation. Moreover, the reduction of lung hyperinflation decreases respiratory workload as shown by the reduction of maximal inspiratory and expiratory pressure. Finally, changes in sputum cellularity showed a reduction in the number of inflammatory cells (neutrophils and macrophages) and an increase in the number of lymphocytes as a result of utilization of the two techniques (previously observed for HFCWO)</offsets><xref rid="b14-copd-13-617" ref-type="bibr"><offsets xml_i="26825" xml_f="26827" txt_i="17467" txt_f="17469">14</offsets></xref><offsets xml_i="26834" xml_f="27084" txt_i="17469" txt_f="17719"> and suggests a modulation of inflammatory cells (greater for IPV). This is the first study that has investigated sputum cellularity for COPD patients; further studies need to confirm our findings, particularly concerning its impact on exacerbations.</offsets></p></sec><sec><title><offsets xml_i="27106" xml_f="27117" txt_i="17721" txt_f="17732">Limitations</offsets></title><p><offsets xml_i="27128" xml_f="27438" txt_i="17733" txt_f="18043">This study has some limitations. It was done in a single center with a relatively modest sample size. We have evaluated only the short-term effects of these techniques; this does not allow us to establish the duration of the effects of the treatment and how many cycles of therapy every patient needs per year.</offsets></p><p><offsets xml_i="27445" xml_f="27775" txt_i="18044" txt_f="18374">Moreover, we have not considered the exacerbations; we should have expected a reduction in the number of exacerbations related with the changes in sputum cellularity. Finally, the absence of a sham ventilation therapy group makes our conclusion somewhat less powerful, especially with regard to subjective factors such as dyspnea.</offsets></p></sec><sec><title><offsets xml_i="27797" xml_f="27807" txt_i="18376" txt_f="18386">Conclusion</offsets></title><p><offsets xml_i="27818" xml_f="28345" txt_i="18387" txt_f="18914">This study shows that both IPV and HFCWO can improve lung function, muscular strength, dyspnea, and scores on health status assessment scales. IPV demonstrated a greater effectiveness in improving test results linked to small bronchial airways and alveolar ventilation (RV and DLCO) and muscular strength (MIP and MEP) as well as scores on daily life and health status assessment scales (BCSS and CAT) compared with HFCWO. These techniques should be considered as additional therapy in patients with severe to very severe COPD.</offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>The authors thank Mr Giles Wilson, Sales Manager Percussionaire Corporation for his valuable help in reviewing the manuscript and Dr Sergio Lanata, Histopathology Unit, Hospital of Sestri Levante, for his valuable help in data analysis and collection. The abstract of this manuscript was presented at the Poster session of Chest Annual Meeting, Austin, October 25–30, 2014. The publication was financially supported by a grant from Medigas Italia srl.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>Disclosure</bold></p><p>The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. The authors report no conflicts of interest in this work.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-copd-13-617"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcoa</surname><given-names>R</given-names></name><name><surname>Rodriguez</surname><given-names>DM</given-names></name><name><surname>Dias</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Classification of Chronic Obstructive Pulmonary Disease (COPD) according to the new Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017: Comparison with GOLD 2011</article-title><source>COPD</source><comment>Epub</comment><year>2017</year><month>11</month><fpage>21</fpage></element-citation></ref><ref id="b2-copd-13-617"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>FL</given-names></name><name><surname>Krahnke</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>V</given-names></name></person-group><article-title>Clinical issue of mucus accumulation in COPD</article-title><source>Int J COPD</source><year>2014</year><volume>9</volume><fpage>139</fpage><lpage>150</lpage></element-citation></ref><ref id="b3-copd-13-617"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brightling</surname><given-names>CE</given-names></name></person-group><article-title>Chronic obstructive pulmonary disease phenotypes, biomarkers and prognostic factors</article-title><source>Allergy Asthma Proc</source><year>2016</year><volume>37</volume><fpage>432</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">27931297</pub-id></element-citation></ref><ref id="b4-copd-13-617"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodruff</surname><given-names>PG</given-names></name><name><surname>Agusti</surname><given-names>A</given-names></name><name><surname>Roche</surname><given-names>N</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name></person-group><article-title>Current concepts in targeting COPD pharmacotherapy: making progress toward personalized management</article-title><source>Lancet</source><year>2015</year><volume>385</volume><fpage>1789</fpage><lpage>1798</lpage><pub-id pub-id-type="pmid">25943943</pub-id></element-citation></ref><ref id="b5-copd-13-617"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bott</surname><given-names>J</given-names></name><name><surname>Blumenthal</surname><given-names>S</given-names></name><name><surname>Buxton</surname><given-names>M</given-names></name><etal></etal><collab>British Thoracic Society Physiotherapy guideline development Group</collab></person-group><article-title>Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patients</article-title><source>Thorax</source><year>2009</year><volume>64</volume><fpage>1</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">19103870</pub-id></element-citation></ref><ref id="b6-copd-13-617"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fagevik Olsen</surname><given-names>M</given-names></name><name><surname>Westerdahl</surname><given-names>E</given-names></name></person-group><article-title>Positive expiratory pressure in patients with chronic obstructive pulmonary disease. A systematic review</article-title><source>Respiration</source><year>2009</year><volume>77</volume><fpage>110</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">18843173</pub-id></element-citation></ref><ref id="b7-copd-13-617"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svenningsen</surname><given-names>S</given-names></name><name><surname>Paulin</surname><given-names>GA</given-names></name><name><surname>Sheikh</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Oscillatory positive expiratory pressure in chronic obstructive pulmonary disease</article-title><source>COPD</source><year>2016</year><volume>13</volume><fpage>66</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">26430763</pub-id></element-citation></ref><ref id="b8-copd-13-617"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piquet</surname><given-names>J</given-names></name><name><surname>Brochard</surname><given-names>L</given-names></name><name><surname>Isabey</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>High frequency chest wall oscillation in patients with chronic air-flow obstruction</article-title><source>Am Rev Respir Dis</source><year>1987</year><volume>136</volume><fpage>1355</fpage><lpage>1359</lpage><pub-id pub-id-type="pmid">3688638</pub-id></element-citation></ref><ref id="b9-copd-13-617"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolini</surname><given-names>A</given-names></name><name><surname>Mollar</surname><given-names>E</given-names></name><name><surname>Grecchi</surname><given-names>B</given-names></name><name><surname>Landucci</surname><given-names>N</given-names></name></person-group><article-title>Comparison of intermittent positive pressure breathing and temporary positive expiratory pressure in patients with severe obstructive pulmonary disease</article-title><source>Arch Bronconeumol</source><year>2014</year><volume>50</volume><fpage>18</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">24321380</pub-id></element-citation></ref><ref id="b10-copd-13-617"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toussaint</surname><given-names>M</given-names></name><name><surname>Guillet</surname><given-names>MC</given-names></name><name><surname>Paternott</surname><given-names>S</given-names></name><name><surname>Soudon</surname><given-names>P</given-names></name><name><surname>Haan</surname><given-names>J</given-names></name></person-group><article-title>Intrapulmonary effects of setting parameters in portable intrapulmonary percussive ventilation devices</article-title><source>Respir Care</source><year>2012</year><volume>57</volume><fpage>735</fpage><lpage>742</lpage><pub-id pub-id-type="pmid">22153619</pub-id></element-citation></ref><ref id="b11-copd-13-617"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venturelli</surname><given-names>E</given-names></name><name><surname>Crisafulli</surname><given-names>E</given-names></name><name><surname>DeBiase</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Efficacy of temporary positive expiratory pressure (TPEP) in patients with lung diseases and chronic mucus hypersecretion. The UNIKO<sup>®</sup> project: a multicentre randomized controlled trial</article-title><source>Clin Rehabil</source><year>2013</year><volume>27</volume><fpage>336</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">22967853</pub-id></element-citation></ref><ref id="b12-copd-13-617"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mascardi</surname><given-names>V</given-names></name><name><surname>Grecchi</surname><given-names>B</given-names></name><name><surname>Barlascini</surname><given-names>C</given-names></name><name><surname>Banfi</surname><given-names>P</given-names></name><name><surname>Nicolini</surname><given-names>A</given-names></name></person-group><article-title>Effectiveness of temporary positive expiratory pressure (T-PEP) at home and at hospital in patients with severe chronic obstructive pulmonary disease</article-title><source>J Thor Dis</source><year>2016</year><volume>8</volume><fpage>2895</fpage><lpage>2902</lpage></element-citation></ref><ref id="b13-copd-13-617"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osadnik</surname><given-names>CR</given-names></name><name><surname>McDonald</surname><given-names>CF</given-names></name><name><surname>Jones</surname><given-names>AP</given-names></name><name><surname>Holland</surname><given-names>AE</given-names></name></person-group><article-title>Airway clearance techniques for chronic obstructive pulmonary disease</article-title><source>Cochrane Database Syst Rev</source><year>2012</year><volume>3</volume><fpage>CD008328</fpage></element-citation></ref><ref id="b14-copd-13-617"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolini</surname><given-names>A</given-names></name><name><surname>Cardini</surname><given-names>F</given-names></name><name><surname>Landucci</surname><given-names>N</given-names></name><name><surname>Lanata</surname><given-names>S</given-names></name><name><surname>Ferrari-Bravo</surname><given-names>M</given-names></name><name><surname>Barlascini</surname><given-names>C</given-names></name></person-group><article-title>Effectiveness of treatment with high-frequency chest wall oscillation in patients with bronchiectasis</article-title><source>BMC Pulm Med</source><year>2013</year><volume>13</volume><fpage>21</fpage><pub-id pub-id-type="pmid">23556995</pub-id></element-citation></ref><ref id="b15-copd-13-617"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lechtzin</surname><given-names>N</given-names></name><name><surname>Wolfe</surname><given-names>LF</given-names></name><name><surname>Frick</surname><given-names>KD</given-names></name></person-group><article-title>The impact of high-frequency chest wall oscillation on healthcare use in patients with neuromuscular diseases</article-title><source>Ann Am Thorac Soc</source><year>2016</year><volume>13</volume><issue>6</issue><fpage>904</fpage><lpage>909</lpage><pub-id pub-id-type="pmid">26999271</pub-id></element-citation></ref><ref id="b16-copd-13-617"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Hanania</surname><given-names>MA</given-names></name><name><surname>Rudell</surname><given-names>K</given-names></name><name><surname>Hackford</surname><given-names>C</given-names></name><name><surname>Tamimi</surname><given-names>N</given-names></name></person-group><article-title>A review of the most common patient-reported outcomes in COPD-revisiting current knowledge and estimating challenges</article-title><source>Int J COPD</source><year>2015</year><volume>10</volume><fpage>725</fpage><lpage>738</lpage></element-citation></ref><ref id="b17-copd-13-617"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leidy</surname><given-names>NK</given-names></name><name><surname>Rennard</surname><given-names>S</given-names></name><name><surname>Schmier</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>K</given-names></name><name><surname>Goldman</surname><given-names>M</given-names></name></person-group><article-title>The breathlessness, cough, and sputum scale. The development of empirically based guidelines for interpretation</article-title><source>Chest</source><year>2003</year><volume>124</volume><fpage>2182</fpage><lpage>2191</lpage><pub-id pub-id-type="pmid">14665499</pub-id></element-citation></ref><ref id="b18-copd-13-617"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leidy</surname><given-names>NK</given-names></name><name><surname>Schmier</surname><given-names>JK</given-names></name><name><surname>Jones</surname><given-names>MK</given-names></name><name><surname>Lloyd</surname><given-names>J</given-names></name><name><surname>Rocchiccioli</surname><given-names>K</given-names></name></person-group><article-title>Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale</article-title><source>Resp Med</source><year>2003</year><volume>97</volume><fpage>S59</fpage><lpage>S70</lpage></element-citation></ref><ref id="b19-copd-13-617"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dodd</surname><given-names>JW</given-names></name><name><surname>Hogg</surname><given-names>L</given-names></name><name><surname>Nolan</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre prospective study</article-title><source>Thorax</source><year>2011</year><volume>66</volume><fpage>425</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">21398686</pub-id></element-citation></ref><ref id="b20-copd-13-617"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>BY</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><etal></etal></person-group><article-title>Validity and reliability of CAT and Dyspnea-12 in bronchiectasis and tuberculosis destroyed lung</article-title><source>Tuber Resp Dis</source><year>2012</year><volume>72</volume><fpage>467</fpage><lpage>474</lpage></element-citation></ref><ref id="b21-copd-13-617"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>MR</given-names></name><name><surname>Hankinson</surname><given-names>J</given-names></name><name><surname>Brusasco</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Standardization of spirometry</article-title><source>Eur Resp J</source><year>2005</year><volume>26</volume><fpage>319</fpage><lpage>338</lpage></element-citation></ref><ref id="b22-copd-13-617"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrino</surname><given-names>R</given-names></name><name><surname>Viegi</surname><given-names>G</given-names></name><name><surname>Brusasco</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Interpretative strategies for lung function tests</article-title><source>Eur Resp J</source><year>2005</year><volume>26</volume><fpage>948</fpage><lpage>968</lpage></element-citation></ref><ref id="b23-copd-13-617"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macintyre</surname><given-names>N</given-names></name><name><surname>Crapo</surname><given-names>RO</given-names></name><name><surname>Viegi</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Standardization of the single-breath determination of carbon monoxide uptake in the lung</article-title><source>Eur Resp J</source><year>2005</year><volume>26</volume><fpage>720</fpage><lpage>735</lpage></element-citation></ref><ref id="b24-copd-13-617"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Thoracic Society/European Respiratory Society</collab></person-group><article-title>ATS/ERS Statement on respiratory muscle testing</article-title><source>Am J Resp Crit Care Med</source><year>2002</year><volume>166</volume><fpage>528</fpage><lpage>621</lpage></element-citation></ref><ref id="b25-copd-13-617"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>JA</given-names></name><name><surname>Whitelaw</surname><given-names>WA</given-names></name></person-group><article-title>The assessment of maximal respiratory mouth pressure in adults</article-title><source>Respir Care</source><year>2009</year><volume>54</volume><fpage>1348</fpage><lpage>1359</lpage><pub-id pub-id-type="pmid">19796415</pub-id></element-citation></ref><ref id="b26-copd-13-617"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Hurd</surname><given-names>SS</given-names></name><name><surname>Agusti</surname><given-names>AG</given-names></name><etal></etal></person-group><article-title>Global strategies for diagnosis and prediction of chronic pulmonary disease. Gold executive summary</article-title><source>Am J Resp Crit Care Med</source><year>2013</year><volume>187</volume><fpage>347</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">22878278</pub-id></element-citation></ref><ref id="b27-copd-13-617"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moritz</surname><given-names>P</given-names></name><name><surname>Steidle</surname><given-names>LJ</given-names></name><name><surname>Felisbino</surname><given-names>MB</given-names></name><name><surname>Kleveston</surname><given-names>T</given-names></name><name><surname>Pizzichini</surname><given-names>MM</given-names></name><name><surname>Pizzichini</surname><given-names>E</given-names></name></person-group><article-title>Determination of the inflammatory component of airway diseases by induced sputum cell counts: use in clinical practice</article-title><source>J Bras Pneumol</source><year>2008</year><volume>34</volume><fpage>913</fpage><lpage>921</lpage><pub-id pub-id-type="pmid">19099097</pub-id></element-citation></ref><ref id="b28-copd-13-617"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staticescu</surname><given-names>S</given-names></name><name><surname>Chereches-Panta</surname><given-names>P</given-names></name><name><surname>Ichimi</surname><given-names>G</given-names></name><name><surname>Valeanu</surname><given-names>M</given-names></name><name><surname>Nanulescu</surname><given-names>MV</given-names></name></person-group><article-title>The value of induced sputum in the diagnosis and management of children with bronchial asthma</article-title><source>Clujul Med</source><year>2014</year><volume>87</volume><fpage>171</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">26528019</pub-id></element-citation></ref><ref id="b29-copd-13-617"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Singh</surname><given-names>D</given-names></name></person-group><article-title>Critical assessment of the value of sputum neutrophils</article-title><source>COPD</source><year>2013</year><volume>10</volume><fpage>107</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">23413897</pub-id></element-citation></ref><ref id="b30-copd-13-617"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varekojis</surname><given-names>SM</given-names></name><name><surname>Douce</surname><given-names>H</given-names></name><name><surname>Flucke</surname><given-names>RL</given-names></name><etal></etal></person-group><article-title>A comparison of the therapeutic effectiveness of and preference for postural drainage and percussion, intrapulmonary percussive ventilation, and high-frequency chest wall compression in hospitalized cystic fibrosis patients</article-title><source>Respir Care</source><year>2003</year><volume>48</volume><fpage>24</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">12556258</pub-id></element-citation></ref><ref id="b31-copd-13-617"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pryor</surname><given-names>JA</given-names></name></person-group><article-title>Physiotherapy for airway clearance in adults</article-title><source>Eur Resp J</source><year>1999</year><volume>14</volume><fpage>1418</fpage><lpage>1424</lpage></element-citation></ref><ref id="b32-copd-13-617"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warnock</surname><given-names>L</given-names></name><name><surname>Gates</surname><given-names>A</given-names></name><name><surname>van der Schans</surname><given-names>CP</given-names></name></person-group><article-title>Chest physiotherapy compared to no chest physiotherapy for cystic fibrosis</article-title><source>Cochrane Database Syst Rev</source><year>2013</year><volume>9</volume><fpage>CD001401</fpage></element-citation></ref><ref id="b33-copd-13-617"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Schans</surname><given-names>CP</given-names></name></person-group><article-title>Conventional chest physical therapy for obstructive lung disease</article-title><source>Respir Care</source><year>2007</year><volume>52</volume><fpage>1198</fpage><lpage>1206</lpage><pub-id pub-id-type="pmid">17716386</pub-id></element-citation></ref><ref id="b34-copd-13-617"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paneroni</surname><given-names>M</given-names></name><name><surname>Clini</surname><given-names>E</given-names></name><name><surname>Simonelli</surname><given-names>C</given-names></name><name><surname>Bianchi</surname><given-names>L</given-names></name><name><surname>Degli Antoni</surname><given-names>F</given-names></name><name><surname>Vitacca</surname><given-names>M</given-names></name></person-group><article-title>Safety and efficacy of short-term intrapulmonary percussive ventilation in patients with bronchiectasis</article-title><source>Respir Care</source><year>2011</year><volume>56</volume><fpage>984</fpage><lpage>988</lpage><pub-id pub-id-type="pmid">21352670</pub-id></element-citation></ref><ref id="b35-copd-13-617"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dmello</surname><given-names>D</given-names></name><name><surname>Navak</surname><given-names>RP</given-names></name><name><surname>Matuschak</surname><given-names>GM</given-names></name></person-group><article-title>High-frequency percussive ventilation for airway clearance in cystic fibrosis: a brief report</article-title><source>Lung</source><year>2010</year><volume>3</volume><fpage>511</fpage><lpage>513</lpage></element-citation></ref><ref id="b36-copd-13-617"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newhouse</surname><given-names>PA</given-names></name><name><surname>White</surname><given-names>F</given-names></name></person-group><article-title>The intrapulmonary percussive ventilation and flutter device compared to chest physiotherapy in patients with cystic fibrosis</article-title><source>Clin Pediatr</source><year>1998</year><volume>37</volume><fpage>427</fpage><lpage>432</lpage></element-citation></ref><ref id="b37-copd-13-617"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Natale</surname><given-names>JE</given-names></name><name><surname>Pfeifle</surname><given-names>J</given-names></name><name><surname>Hommick</surname><given-names>DN</given-names></name></person-group><article-title>Comparison of intrapulmonary percussive ventilation and chest physiotherapy: a pilot study in patients with cystic fibrosis</article-title><source>Chest</source><year>1994</year><volume>105</volume><fpage>1789</fpage><lpage>1793</lpage><pub-id pub-id-type="pmid">8205878</pub-id></element-citation></ref><ref id="b38-copd-13-617"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homnick</surname><given-names>DN</given-names></name><name><surname>White</surname><given-names>F</given-names></name><name><surname>de Castro</surname><given-names>C</given-names></name></person-group><article-title>Comparison of effects of an intrapulmonary percussive ventilator to standard aerosol and chest physiotherapy in treatment of cystic fibrosis</article-title><source>Pediatr Pulmonol</source><year>1995</year><volume>20</volume><fpage>50</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">7478782</pub-id></element-citation></ref><ref id="b39-copd-13-617"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Ginderdeuren</surname><given-names>F</given-names></name><name><surname>Verbanck</surname><given-names>S</given-names></name><name><surname>Van Cauwelaert</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Chest physiotherapy in cystic fibrosis: short-term effects of autogenic drainage preceded by wet inhalation of saline versus autogenic drainage preceded by intrapulmonary percussive ventilation with saline</article-title><source>Respiration</source><year>2008</year><volume>100</volume><fpage>1526</fpage><lpage>1533</lpage></element-citation></ref><ref id="b40-copd-13-617"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arens</surname><given-names>R</given-names></name><name><surname>Gozal</surname><given-names>D</given-names></name><name><surname>Omlin</surname><given-names>KJ</given-names></name><etal></etal></person-group><article-title>Comparison of high frequency chest compression and conventional chest physiotherapy in hospitalized patients with cystic fibrosis</article-title><source>Am J Resp Crit Care Med</source><year>1994</year><volume>150</volume><fpage>1154</fpage><lpage>1157</lpage><pub-id pub-id-type="pmid">7921452</pub-id></element-citation></ref><ref id="b41-copd-13-617"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Darbee</surname><given-names>JC</given-names></name><name><surname>Kanga</surname><given-names>JF</given-names></name><name><surname>Ohtake</surname><given-names>PJ</given-names></name></person-group><article-title>Physiologic evidence for high-frequency chest wall oscillation and positive expiratory pressure breathing in hospitalized subjects with cystic fibrosis</article-title><source>Phys Ther</source><year>2005</year><volume>85</volume><fpage>1278</fpage><lpage>1289</lpage><pub-id pub-id-type="pmid">16305267</pub-id></element-citation></ref><ref id="b42-copd-13-617"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phililips</surname><given-names>GE</given-names></name><name><surname>Pike</surname><given-names>SE</given-names></name><name><surname>Jaffe’</surname><given-names>A</given-names></name><name><surname>Bush</surname><given-names>A</given-names></name></person-group><article-title>Comparison of active cycle of breathing and high-frequency oscillation jacket in children with cystic fibrosis</article-title><source>Pediatr Pulmonol</source><year>2004</year><volume>37</volume><fpage>71</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">14679493</pub-id></element-citation></ref><ref id="b43-copd-13-617"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempainen</surname><given-names>RR</given-names></name><name><surname>Milla</surname><given-names>C</given-names></name><name><surname>Dunitz</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Comparison of settings used for high-frequency chest-wall compression in cystic fibrosis</article-title><source>Respir Care</source><year>2010</year><volume>55</volume><issue>6</issue><fpage>695</fpage><lpage>701</lpage><pub-id pub-id-type="pmid">20507651</pub-id></element-citation></ref><ref id="b44-copd-13-617"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fainardi</surname><given-names>V</given-names></name><name><surname>Longo</surname><given-names>F</given-names></name><name><surname>Faverzani</surname><given-names>S</given-names></name><name><surname>Tripodi</surname><given-names>MC</given-names></name><name><surname>Chetta</surname><given-names>A</given-names></name><name><surname>Pisi</surname><given-names>G</given-names></name></person-group><article-title>Short-term effects of high-frequency chest compression and positive expiratory pressure in patients with cystic fibrosis</article-title><source>J Clin Med Res</source><year>2011</year><volume>3</volume><issue>6</issue><fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">22393338</pub-id></element-citation></ref><ref id="b45-copd-13-617"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oermann</surname><given-names>CM</given-names></name><name><surname>Stroker</surname><given-names>MM</given-names></name><name><surname>Giles</surname><given-names>D</given-names></name><name><surname>Sontag</surname><given-names>M</given-names></name><name><surname>Accurso</surname><given-names>FJ</given-names></name><name><surname>Castile</surname><given-names>RG</given-names></name></person-group><article-title>Comparison of high-frequency chest wall oscillation and oscillating positive expiratory pressure in the home management of cystic fibrosis: a pilot study</article-title><source>Pediatr Pulmonol</source><year>2001</year><volume>32</volume><fpage>372</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">11596162</pub-id></element-citation></ref><ref id="b46-copd-13-617"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kempainen</surname><given-names>RR</given-names></name><name><surname>Williams</surname><given-names>CB</given-names></name><name><surname>Hazelwood</surname><given-names>A</given-names></name><name><surname>Rubin</surname><given-names>BK</given-names></name><name><surname>Milla</surname><given-names>CE</given-names></name></person-group><article-title>Comparison of high-frequency chest wall oscillation with differing waveform for airway clearance in cystic fibrosis</article-title><source>Chest</source><year>2007</year><volume>132</volume><fpage>1227</fpage><lpage>1232</lpage><pub-id pub-id-type="pmid">17890465</pub-id></element-citation></ref><ref id="b47-copd-13-617"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mcllwaine</surname><given-names>MP</given-names></name><name><surname>Alarie</surname><given-names>N</given-names></name><name><surname>Davidson</surname><given-names>GF</given-names></name><etal></etal></person-group><article-title>Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis</article-title><source>Thorax</source><year>2013</year><volume>68</volume><fpage>746</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">23407019</pub-id></element-citation></ref><ref id="b48-copd-13-617"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osman</surname><given-names>LP</given-names></name><name><surname>Roughton</surname><given-names>M</given-names></name><name><surname>Hodson</surname><given-names>ME</given-names></name><name><surname>Pryor</surname><given-names>JA</given-names></name></person-group><article-title>Short-term comparative of high frequency chest wall oscillation and European airway clearance techniques in patients with cystic fibrosis</article-title><source>Thorax</source><year>2010</year><volume>65</volume><fpage>196</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">19703826</pub-id></element-citation></ref><ref id="b49-copd-13-617"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degreef</surname><given-names>JM</given-names></name><name><surname>Crepin</surname><given-names>JL</given-names></name><name><surname>Deroubalx</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Reduction du nombre de superinfections bronchiques par la ventilation a percussion intrapulmonaire, chez de patients atteints de bronchopneumopaties chroniques obstructives (BPCO) ou de bronchiectasies (DDB)</article-title><source>Rev Mal Resp</source><year>2003</year><volume>1S89</volume><fpage>129</fpage></element-citation></ref><ref id="b50-copd-13-617"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nava</surname><given-names>S</given-names></name><name><surname>Barbarito</surname><given-names>N</given-names></name><name><surname>Piaggi</surname><given-names>G</given-names></name><name><surname>De Mattia</surname><given-names>E</given-names></name><name><surname>Cirio</surname><given-names>S</given-names></name></person-group><article-title>Physiological response to intrapulmonary percussive ventilation in stable COPD patients</article-title><source>Respir Med</source><year>2006</year><volume>100</volume><fpage>1526</fpage><lpage>1533</lpage><pub-id pub-id-type="pmid">16490350</pub-id></element-citation></ref><ref id="b51-copd-13-617"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Testa</surname><given-names>A</given-names></name><name><surname>Galeri</surname><given-names>S</given-names></name><name><surname>Villafane</surname><given-names>JH</given-names></name><name><surname>Corbellini</surname><given-names>C</given-names></name><name><surname>Pillastrini</surname><given-names>P</given-names></name><name><surname>Negrini</surname><given-names>S</given-names></name></person-group><article-title>Efficacy of short-term intrapulmonary percussive ventilation in patients with chronic obstructive pulmonary disease</article-title><source>Disabil Rehabil</source><year>2015</year><volume>37</volume><fpage>899</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">25098596</pub-id></element-citation></ref><ref id="b52-copd-13-617"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vargas</surname><given-names>F</given-names></name><name><surname>Boyer</surname><given-names>A</given-names></name><name><surname>Bui</surname><given-names>HN</given-names></name><name><surname>Guenard</surname><given-names>H</given-names></name><name><surname>Gruson</surname><given-names>D</given-names></name><name><surname>Hilbert</surname><given-names>G</given-names></name></person-group><article-title>Effect of intrapulmonary percussive ventilation on expiratory flow limitation in chronic obstructive pulmonary disease patients</article-title><source>J Crit Care</source><year>2009</year><volume>24</volume><fpage>212</fpage><lpage>219</lpage><pub-id pub-id-type="pmid">19327288</pub-id></element-citation></ref><ref id="b53-copd-13-617"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vargas</surname><given-names>F</given-names></name><name><surname>Bui</surname><given-names>NH</given-names></name><name><surname>Boyer</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Intrapulmonary percussive ventilation in acute exacerbation of COPD patients with mild respiratory acidosis: a randomized controlled trial</article-title><source>Crit Care</source><year>2005</year><volume>9</volume><fpage>R382</fpage><lpage>R389</lpage><pub-id pub-id-type="pmid">16137351</pub-id></element-citation></ref><ref id="b54-copd-13-617"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonaglia</surname><given-names>V</given-names></name><name><surname>Lucangelo</surname><given-names>U</given-names></name><name><surname>Zin</surname><given-names>WA</given-names></name><etal></etal></person-group><article-title>Intrapulmonary percussive ventilation improves the outcome of patients with acute exacerbations of COPD using helmet</article-title><source>Crit Care Med</source><year>2006</year><volume>34</volume><fpage>2940</fpage><lpage>2945</lpage><pub-id pub-id-type="pmid">17075375</pub-id></element-citation></ref><ref id="b55-copd-13-617"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimassi</surname><given-names>S</given-names></name><name><surname>Vargas</surname><given-names>F</given-names></name><name><surname>Lyazidi</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Intrapulmonary percussive ventilation superimposed on spontaneous breathing: a physiological study in patients at risk for extubation failure</article-title><source>Intensive Care Med</source><year>2011</year><volume>37</volume><fpage>1269</fpage><lpage>1276</lpage><pub-id pub-id-type="pmid">21656293</pub-id></element-citation></ref><ref id="b56-copd-13-617"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ides</surname><given-names>K</given-names></name><name><surname>Vos</surname><given-names>W</given-names></name><name><surname>de Backer</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Acute effects of intrapulmonary percussive ventilation in COPD patients assessed by using conventional outcome parameters and a novel computational fluid dynamics technique</article-title><source>Int J COPD</source><year>2012</year><volume>7</volume><fpage>667</fpage><lpage>671</lpage></element-citation></ref><ref id="b57-copd-13-617"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clini</surname><given-names>EM</given-names></name><name><surname>Antoni</surname><given-names>FD</given-names></name><name><surname>Vitacca</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Intrapulmonary percussive ventilation in tracheostomized patients: a randomized controlled trial</article-title><source>Intensive Care Med</source><year>2006</year><volume>32</volume><fpage>1994</fpage><lpage>2001</lpage><pub-id pub-id-type="pmid">17061020</pub-id></element-citation></ref><ref id="b58-copd-13-617"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braverman</surname><given-names>J</given-names></name><name><surname>Nozzarella</surname><given-names>MJ</given-names></name></person-group><article-title>High-frequency chest compression: advanced therapy for obstructive lung disease</article-title><source>Respir Ther</source><year>2007</year><volume>2</volume><fpage>48</fpage><lpage>51</lpage></element-citation></ref><ref id="b59-copd-13-617"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahajan</surname><given-names>AK</given-names></name><name><surname>Diette</surname><given-names>GB</given-names></name><name><surname>Hatipoglu</surname><given-names>U</given-names></name><etal></etal></person-group><article-title>High frequency chest wall oscillation for asthma and chronic obstructive pulmonary disease exacerbations: a randomized sham-controlled clinical trial</article-title><source>Respir Res</source><year>2011</year><volume>12</volume><fpage>20</fpage><pub-id pub-id-type="pmid">21294865</pub-id></element-citation></ref><ref id="b60-copd-13-617"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakravorty</surname><given-names>I</given-names></name><name><surname>Chahal</surname><given-names>K</given-names></name><name><surname>Austin</surname><given-names>G</given-names></name></person-group><article-title>A pilot study of the impact of high-frequency chest wall oscillation in chronic obstructive pulmonary disease patients with mucus hypersecretion</article-title><source>Int J COPD</source><year>2011</year><volume>6</volume><fpage>693</fpage><lpage>699</lpage></element-citation></ref><ref id="b61-copd-13-617"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bidiwala</surname><given-names>A</given-names></name><name><surname>Volpe</surname><given-names>L</given-names></name><name><surname>Halaby</surname><given-names>C</given-names></name><name><surname>Fazzari</surname><given-names>M</given-names></name><name><surname>Valsamis</surname><given-names>C</given-names></name><name><surname>Pirzada</surname><given-names>M</given-names></name></person-group><article-title>A comparison of high frequency chest wall oscillation and intrapulmonary percussive ventilation for airway clearance in pediatric patients with tracheostomy</article-title><source>Postgrad Med</source><year>2017</year><volume>129</volume><fpage>276</fpage><lpage>282</lpage><pub-id pub-id-type="pmid">27882804</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-copd-13-617" position="float"><label>Figure 1</label><caption><p>Flow chart detailing study methodology.</p><p><bold>Abbreviations:</bold> GOLD, Global Initiative for Chronic Obstructive Lung Diseases; FEV<sub>1</sub>, forced expiratory volume 1 second; HFCWO, high-frequency chest wall oscillation; IPV, intrapulmonary percussive ventilation.</p></caption><graphic xlink:href="copd-13-617Fig1"></graphic></fig><fig id="f2-copd-13-617" position="float"><label>Figure 2</label><caption><p>(<bold>A</bold>) Intrapulmonary percussive ventilator. (<bold>B</bold>) High-frequency chest wall oscillator.</p></caption><graphic xlink:href="copd-13-617Fig2"></graphic></fig><fig id="f3-copd-13-617" position="float"><label>Figure 3</label><caption><p>Median changes in BCSS and CAT before and after treatment in the three groups.</p><p><bold>Abbreviations:</bold> BCSS, Breath, Cough and Sputum Scale; CAT, COPD Assessment Test; HFCWO, high-frequency chest wall oscillation; IPV, intrapulmonary percussive ventilation.</p></caption><graphic xlink:href="copd-13-617Fig3"></graphic></fig><table-wrap id="t1-copd-13-617" position="float"><label>Table 1</label><caption><p>Demographic, clinical, and functional parameters at baseline in the three groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="left" rowspan="1" colspan="1">Control group<break></break>(n=22)</th><th valign="top" align="left" rowspan="1" colspan="1">IPV group<break></break>(n=20)</th><th valign="top" align="left" rowspan="1" colspan="1">HFCWO group<break></break>(n=21)</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td colspan="5" valign="top" align="left" rowspan="1">Demographic and clinical characteristics</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1">74.9±2.7</td><td valign="top" align="left" rowspan="1" colspan="1">72.8±6.1</td><td valign="top" align="left" rowspan="1" colspan="1">73.8±5.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.22</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Male (%)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (50.0)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (75.0)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (42.8)</td><td valign="top" align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> BMI (kg/m<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">25.9±3.7</td><td valign="top" align="left" rowspan="1" colspan="1">25.8±4.3</td><td valign="top" align="left" rowspan="1" colspan="1">24.9±5.8</td><td valign="top" align="left" rowspan="1" colspan="1">0.11</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Exacerbations per year (n)</td><td valign="top" align="left" rowspan="1" colspan="1">2.3±0.3</td><td valign="top" align="left" rowspan="1" colspan="1">2.4±0.2</td><td valign="top" align="left" rowspan="1" colspan="1">2.5±0.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.12</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> Hospitalizations per year (n)</td><td valign="top" align="left" rowspan="1" colspan="1">1.1±0.3</td><td valign="top" align="left" rowspan="1" colspan="1">1.3±0.4</td><td valign="top" align="left" rowspan="1" colspan="1">1.2±0.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.14</td></tr><tr><td colspan="5" valign="top" align="left" rowspan="1">Clinical and functional parameters</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> PaO<sub>2</sub></td><td valign="top" align="left" rowspan="1" colspan="1">69.8±10.4</td><td valign="top" align="left" rowspan="1" colspan="1">71.8±7.8</td><td valign="top" align="left" rowspan="1" colspan="1">72.0±10.0</td><td valign="top" align="left" rowspan="1" colspan="1">0.18</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> PaCO<sub>2</sub></td><td valign="top" align="left" rowspan="1" colspan="1">41.7±6.0</td><td valign="top" align="left" rowspan="1" colspan="1">42.5±4.8</td><td valign="top" align="left" rowspan="1" colspan="1">41.8±2.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.21</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> pH</td><td valign="top" align="left" rowspan="1" colspan="1">7.4±0</td><td valign="top" align="left" rowspan="1" colspan="1">7.4±0</td><td valign="top" align="left" rowspan="1" colspan="1">7.4±0</td><td valign="top" align="left" rowspan="1" colspan="1">0.19</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> HCO<sub>3</sub></td><td valign="top" align="left" rowspan="1" colspan="1">24.6±1.5</td><td valign="top" align="left" rowspan="1" colspan="1">23.3±2.0</td><td valign="top" align="left" rowspan="1" colspan="1">24.8±1.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> FVC%</td><td valign="top" align="left" rowspan="1" colspan="1">61.1 (16.3)</td><td valign="top" align="left" rowspan="1" colspan="1">58.7 (13.4)</td><td valign="top" align="left" rowspan="1" colspan="1">56.4 (13.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0.15</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> FEV<sub>1</sub>%</td><td valign="top" align="left" rowspan="1" colspan="1">36.2±2.7</td><td valign="top" align="left" rowspan="1" colspan="1">36.7±1.8</td><td valign="top" align="left" rowspan="1" colspan="1">38.9±2.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> FEV<sub>1</sub>/FVC%</td><td valign="top" align="left" rowspan="1" colspan="1">46.1±12.7</td><td valign="top" align="left" rowspan="1" colspan="1">48.8±13.7</td><td valign="top" align="left" rowspan="1" colspan="1">56.9±10.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> TLC%</td><td valign="top" align="left" rowspan="1" colspan="1">140.6±22.2</td><td valign="top" align="left" rowspan="1" colspan="1">117.3±31.7</td><td valign="top" align="left" rowspan="1" colspan="1">132.5±34.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.11</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> RV%</td><td valign="top" align="left" rowspan="1" colspan="1">192.4±67.0</td><td valign="top" align="left" rowspan="1" colspan="1">183.0±66.8</td><td valign="top" align="left" rowspan="1" colspan="1">149.6±39.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> DLCO%</td><td valign="top" align="left" rowspan="1" colspan="1">52.9±5.6</td><td valign="top" align="left" rowspan="1" colspan="1">60.6±15.0</td><td valign="top" align="left" rowspan="1" colspan="1">65.8±12.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> MIP</td><td valign="top" align="left" rowspan="1" colspan="1">5.7±2.0</td><td valign="top" align="left" rowspan="1" colspan="1">6.2±2.0</td><td valign="top" align="left" rowspan="1" colspan="1">6.6±3.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.09</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> MEP</td><td valign="top" align="left" rowspan="1" colspan="1">6.5±2.7</td><td valign="top" align="left" rowspan="1" colspan="1">7.4±1.9</td><td valign="top" align="left" rowspan="1" colspan="1">7.1±1.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.08</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> 6MWT (mt)</td><td valign="top" align="left" rowspan="1" colspan="1">240±30</td><td valign="top" align="left" rowspan="1" colspan="1">242±26</td><td valign="top" align="left" rowspan="1" colspan="1">265±55</td><td valign="top" align="left" rowspan="1" colspan="1">0.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> CRP</td><td valign="top" align="left" rowspan="1" colspan="1">0.5±0.4</td><td valign="top" align="left" rowspan="1" colspan="1">1.0±0.7</td><td valign="top" align="left" rowspan="1" colspan="1">1.5±1.6</td><td valign="top" align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> ϒGL</td><td valign="top" align="left" rowspan="1" colspan="1">12.7±3.9</td><td valign="top" align="left" rowspan="1" colspan="1">15.0±2.0</td><td valign="top" align="left" rowspan="1" colspan="1">16.8±5.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.06</td></tr><tr><td colspan="5" valign="top" align="left" rowspan="1">Scales</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> mMRC scale</td><td valign="top" align="left" rowspan="1" colspan="1">3.2±0.9</td><td valign="top" align="left" rowspan="1" colspan="1">2.7±0.9</td><td valign="top" align="left" rowspan="1" colspan="1">2.5±1.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.07</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> CAT score</td><td valign="top" align="left" rowspan="1" colspan="1">23.2±8.1</td><td valign="top" align="left" rowspan="1" colspan="1">24.1±5.9</td><td valign="top" align="left" rowspan="1" colspan="1">24.6±5.8</td><td valign="top" align="left" rowspan="1" colspan="1">0.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"> BCSS</td><td valign="top" align="left" rowspan="1" colspan="1">4.9±1.4</td><td valign="top" align="left" rowspan="1" colspan="1">6.3±1.4</td><td valign="top" align="left" rowspan="1" colspan="1">6.4±2.6</td><td valign="top" align="left" rowspan="1" colspan="1">0.06</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-copd-13-617"><p><bold>Notes:</bold> Data are expressed as mean ± SD, unless otherwise stated. <italic>p</italic>-value &lt;0.05; F-test for continuous variables and <italic>χ</italic><sup>2</sup> for categorical variables.</p></fn><fn id="tfn2-copd-13-617"><p><bold>Abbreviations:</bold> 6MWT, 6-minute walk test; ϒGL, gammaglobulin; BCSS, Breathlessness, Cough and Sputum Scale; BMI, body mass index; CAT, COPD Assessment Test; CRP, C-reactive protein; DLCO, diffusing lung capacity monoxide; FEV<sub>1</sub>, forced expiratory volume in 1 second; FVC, forced vital capacity; HFCWO, high-frequency chest wall oscillation; IPV, intrapulmonary percussive ventilation; MEP, maximal expiratory pressure; MIP, maximal inspiratory pressure; mMRC, modified Medical Research Council; RV, residual volume; TLC, total lung capacity.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-copd-13-617" position="float"><label>Table 2</label><caption><p>Results of primary outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1"></th><th colspan="3" valign="top" align="left" rowspan="1">Before treatment
<hr></hr></th><th colspan="3" valign="top" align="left" rowspan="1">After treatment
<hr></hr></th><th colspan="3" valign="top" align="left" rowspan="1">Regression analysis <italic>p</italic>-value
<hr></hr></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Control group</th><th valign="top" align="left" rowspan="1" colspan="1">IPV group</th><th valign="top" align="left" rowspan="1" colspan="1">HFCWO group</th><th valign="top" align="left" rowspan="1" colspan="1">Control group</th><th valign="top" align="left" rowspan="1" colspan="1">IPV group</th><th valign="top" align="left" rowspan="1" colspan="1">HFCWO group</th><th valign="top" align="left" rowspan="1" colspan="1">IPV vs control</th><th valign="top" align="left" rowspan="1" colspan="1">HFCWO vs control</th><th valign="top" align="left" rowspan="1" colspan="1">IPV vs HFCWO</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex =0</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">9</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sex =1</td><td valign="top" align="left" rowspan="1" colspan="1">10</td><td valign="top" align="left" rowspan="1" colspan="1">5</td><td valign="top" align="left" rowspan="1" colspan="1">11</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="left" rowspan="1" colspan="1">74±3</td><td valign="top" align="left" rowspan="1" colspan="1">72±7</td><td valign="top" align="left" rowspan="1" colspan="1">74±6</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BCSS</td><td valign="top" align="left" rowspan="1" colspan="1">4.6±1.7</td><td valign="top" align="left" rowspan="1" colspan="1">6.3±1.4</td><td valign="top" align="left" rowspan="1" colspan="1">6.6±2.8</td><td valign="top" align="left" rowspan="1" colspan="1">5.5±2.1</td><td valign="top" align="left" rowspan="1" colspan="1">3.1±1.7</td><td valign="top" align="left" rowspan="1" colspan="1">5.2±2.2</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.007</td><td valign="top" align="left" rowspan="1" colspan="1">0.001<sup>*</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">mMRC</td><td valign="top" align="left" rowspan="1" colspan="1">3.1±0.8</td><td valign="top" align="left" rowspan="1" colspan="1">2.7±0.9</td><td valign="top" align="left" rowspan="1" colspan="1">2.5±1.0</td><td valign="top" align="left" rowspan="1" colspan="1">3.2±0.8</td><td valign="top" align="left" rowspan="1" colspan="1">2.4±0.9</td><td valign="top" align="left" rowspan="1" colspan="1">2.4±0.9</td><td valign="top" align="left" rowspan="1" colspan="1">0.01<sup>**</sup></td><td valign="top" align="left" rowspan="1" colspan="1">0.04<sup>**</sup></td><td valign="top" align="left" rowspan="1" colspan="1">0.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CAT</td><td valign="top" align="left" rowspan="1" colspan="1">23.7±7.4</td><td valign="top" align="left" rowspan="1" colspan="1">24.7±5.9</td><td valign="top" align="left" rowspan="1" colspan="1">24.9±6.4</td><td valign="top" align="left" rowspan="1" colspan="1">26.9±7.6</td><td valign="top" align="left" rowspan="1" colspan="1">17.0±6.3</td><td valign="top" align="left" rowspan="1" colspan="1">20.9±6.9</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">,0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.02<sup>**</sup></td></tr></tbody></table><table-wrap-foot><fn id="tfn3-copd-13-617"><p><bold>Note:</bold> Data are expressed as mean ± SD.</p></fn><fn id="tfn4-copd-13-617"><p><bold>Abbreviations:</bold> BCSS, Breathlessness, Cough and Sputum Scale; CAT, COPD Assessment Test; HFCWO, high-frequency chest wall oscillation; IPV, intrapulmonary percussive ventilation; mMRC, modified Medical Research Council.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-copd-13-617" position="float"><label>Table 3</label><caption><p>Results of secondary outcomes (hematological, biochemical, and respiratory function parameters)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Variable</th><th colspan="3" valign="top" align="left" rowspan="1">Before treatment
<hr></hr></th><th colspan="3" valign="top" align="left" rowspan="1">After treatment
<hr></hr></th><th colspan="3" valign="top" align="left" rowspan="1">Regression analysis<break></break><italic>p</italic>-value
<hr></hr></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Control group</th><th valign="top" align="left" rowspan="1" colspan="1">IPV group</th><th valign="top" align="left" rowspan="1" colspan="1">HFCWO group</th><th valign="top" align="left" rowspan="1" colspan="1">Control group</th><th valign="top" align="left" rowspan="1" colspan="1">IPV group</th><th valign="top" align="left" rowspan="1" colspan="1">HFCWO group</th><th valign="top" align="left" rowspan="1" colspan="1">Control/IPV</th><th valign="top" align="left" rowspan="1" colspan="1">Control/HFCWO</th><th valign="top" align="left" rowspan="1" colspan="1">IPV/HFCWO</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Leukocytes</td><td valign="top" align="left" rowspan="1" colspan="1">8.033±1.749</td><td valign="top" align="left" rowspan="1" colspan="1">7.938±1.886</td><td valign="top" align="left" rowspan="1" colspan="1">7.433±2.028</td><td valign="top" align="left" rowspan="1" colspan="1">9.335±1.558</td><td valign="top" align="left" rowspan="1" colspan="1">7.519±1.907</td><td valign="top" align="left" rowspan="1" colspan="1">7.155±1.755</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Neutrophils%</td><td valign="top" align="left" rowspan="1" colspan="1">65±9</td><td valign="top" align="left" rowspan="1" colspan="1">70±11</td><td valign="top" align="left" rowspan="1" colspan="1">66±9</td><td valign="top" align="left" rowspan="1" colspan="1">71±9</td><td valign="top" align="left" rowspan="1" colspan="1">66±8</td><td valign="top" align="left" rowspan="1" colspan="1">63±8</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lymphocytes%</td><td valign="top" align="left" rowspan="1" colspan="1">29±5</td><td valign="top" align="left" rowspan="1" colspan="1">21±7</td><td valign="top" align="left" rowspan="1" colspan="1">24±8</td><td valign="top" align="left" rowspan="1" colspan="1">25±6</td><td valign="top" align="left" rowspan="1" colspan="1">23±6</td><td valign="top" align="left" rowspan="1" colspan="1">26±7</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CRP</td><td valign="top" align="left" rowspan="1" colspan="1">0.5±0.5</td><td valign="top" align="left" rowspan="1" colspan="1">1.0±0.7</td><td valign="top" align="left" rowspan="1" colspan="1">1.5±1.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.8±0.5</td><td valign="top" align="left" rowspan="1" colspan="1">0.6±0.4</td><td valign="top" align="left" rowspan="1" colspan="1">0.9±0.9</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FVC</td><td valign="top" align="left" rowspan="1" colspan="1">2.609±0.738</td><td valign="top" align="left" rowspan="1" colspan="1">1.989±0.839</td><td valign="top" align="left" rowspan="1" colspan="1">2.078±0.701</td><td valign="top" align="left" rowspan="1" colspan="1">2.414±0.919</td><td valign="top" align="left" rowspan="1" colspan="1">2.256±0.804</td><td valign="top" align="left" rowspan="1" colspan="1">2.269±0.633</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FVC%</td><td valign="top" align="left" rowspan="1" colspan="1">65±10</td><td valign="top" align="left" rowspan="1" colspan="1">60±16</td><td valign="top" align="left" rowspan="1" colspan="1">66±12</td><td valign="top" align="left" rowspan="1" colspan="1">59±12</td><td valign="top" align="left" rowspan="1" colspan="1">68±13</td><td valign="top" align="left" rowspan="1" colspan="1">71±9</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub></td><td valign="top" align="left" rowspan="1" colspan="1">1.155±0.504</td><td valign="top" align="left" rowspan="1" colspan="1">1.013±0.568</td><td valign="top" align="left" rowspan="1" colspan="1">1.236±0.543</td><td valign="top" align="left" rowspan="1" colspan="1">1.045±0.446</td><td valign="top" align="left" rowspan="1" colspan="1">1.195±0.618</td><td valign="top" align="left" rowspan="1" colspan="1">1.349±0.554</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub>%</td><td valign="top" align="left" rowspan="1" colspan="1">35±9</td><td valign="top" align="left" rowspan="1" colspan="1">37±12</td><td valign="top" align="left" rowspan="1" colspan="1">43±11</td><td valign="top" align="left" rowspan="1" colspan="1">31±9</td><td valign="top" align="left" rowspan="1" colspan="1">44.0±2.1</td><td valign="top" align="left" rowspan="1" colspan="1">45.7±3.6</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FEV<sub>1</sub>/FVC%</td><td valign="top" align="left" rowspan="1" colspan="1">45.6%±13.4%</td><td valign="top" align="left" rowspan="1" colspan="1">48.8%±13.0%</td><td valign="top" align="left" rowspan="1" colspan="1">57.5%±11.9%</td><td valign="top" align="left" rowspan="1" colspan="1">43.9%±12.2%</td><td valign="top" align="left" rowspan="1" colspan="1">51.8%±11.0%</td><td valign="top" align="left" rowspan="1" colspan="1">58.8%±13.4%</td><td valign="top" align="left" rowspan="1" colspan="1">0.04</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td><td valign="top" align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLC</td><td valign="top" align="left" rowspan="1" colspan="1">5.799±1.347</td><td valign="top" align="left" rowspan="1" colspan="1">7.381±2.047</td><td valign="top" align="left" rowspan="1" colspan="1">5.458±1.426</td><td valign="top" align="left" rowspan="1" colspan="1">5.847±1.024</td><td valign="top" align="left" rowspan="1" colspan="1">5.859±1.168</td><td valign="top" align="left" rowspan="1" colspan="1">5.247±1.355</td><td valign="top" align="left" rowspan="1" colspan="1">0.01</td><td valign="top" align="left" rowspan="1" colspan="1">0.04</td><td valign="top" align="left" rowspan="1" colspan="1">0.03</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLC%</td><td valign="top" align="left" rowspan="1" colspan="1">139.±21</td><td valign="top" align="left" rowspan="1" colspan="1">147.±31</td><td valign="top" align="left" rowspan="1" colspan="1">133±35</td><td valign="top" align="left" rowspan="1" colspan="1">145±18</td><td valign="top" align="left" rowspan="1" colspan="1">137±23</td><td valign="top" align="left" rowspan="1" colspan="1">124±28</td><td valign="top" align="left" rowspan="1" colspan="1">0.01</td><td valign="top" align="left" rowspan="1" colspan="1">0.04</td><td valign="top" align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RV</td><td valign="top" align="left" rowspan="1" colspan="1">3.731±0.758</td><td valign="top" align="left" rowspan="1" colspan="1">4.106±1.805</td><td valign="top" align="left" rowspan="1" colspan="1">3.453±1.296</td><td valign="top" align="left" rowspan="1" colspan="1">3.781±718</td><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">3.299±1.153</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td><td valign="top" align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RV%</td><td valign="top" align="left" rowspan="1" colspan="1">190±67</td><td valign="top" align="left" rowspan="1" colspan="1">183±66</td><td valign="top" align="left" rowspan="1" colspan="1">146±37</td><td valign="top" align="left" rowspan="1" colspan="1">203±66</td><td valign="top" align="left" rowspan="1" colspan="1">150±36</td><td valign="top" align="left" rowspan="1" colspan="1">136±29</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td><td valign="top" align="left" rowspan="1" colspan="1">0.02</td><td valign="top" align="left" rowspan="1" colspan="1">0.04</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RV/TLC%</td><td valign="top" align="left" rowspan="1" colspan="1">65.1%±9.7%</td><td valign="top" align="left" rowspan="1" colspan="1">67.0%±13.5%</td><td valign="top" align="left" rowspan="1" colspan="1">59.6%±9.7%</td><td valign="top" align="left" rowspan="1" colspan="1">67.9%±13.0%</td><td valign="top" align="left" rowspan="1" colspan="1">63.6%±8.1%</td><td valign="top" align="left" rowspan="1" colspan="1">60.5%±9.7%</td><td valign="top" align="left" rowspan="1" colspan="1">0.01</td><td valign="top" align="left" rowspan="1" colspan="1">0.01</td><td valign="top" align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DLCO%</td><td valign="top" align="left" rowspan="1" colspan="1">51.0%±5.7%</td><td valign="top" align="left" rowspan="1" colspan="1">60.6%±15.0%</td><td valign="top" align="left" rowspan="1" colspan="1">67.5%±12.3%</td><td valign="top" align="left" rowspan="1" colspan="1">48.5%±14.1%</td><td valign="top" align="left" rowspan="1" colspan="1">67.8%±9.1%</td><td valign="top" align="left" rowspan="1" colspan="1">69.7%±5.7%</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MIP (kPa)</td><td valign="top" align="left" rowspan="1" colspan="1">5.8±2.1</td><td valign="top" align="left" rowspan="1" colspan="1">6.2±2.0</td><td valign="top" align="left" rowspan="1" colspan="1">6.8±2.3</td><td valign="top" align="left" rowspan="1" colspan="1">5.3±1.8</td><td valign="top" align="left" rowspan="1" colspan="1">8.1±2.0</td><td valign="top" align="left" rowspan="1" colspan="1">7.5±2.8</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.004</td><td valign="top" align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">MEP (kPa)</td><td valign="top" align="left" rowspan="1" colspan="1">6.4±2.4</td><td valign="top" align="left" rowspan="1" colspan="1">7.4±1.9</td><td valign="top" align="left" rowspan="1" colspan="1">7.2±2.1</td><td valign="top" align="left" rowspan="1" colspan="1">5.8±2.0</td><td valign="top" align="left" rowspan="1" colspan="1">9.3±1.4</td><td valign="top" align="left" rowspan="1" colspan="1">8.0±2.4</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.01</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">pO<sub>2</sub></td><td valign="top" align="left" rowspan="1" colspan="1">69.1±10.1</td><td valign="top" align="left" rowspan="1" colspan="1">71.8±7.8</td><td valign="top" align="left" rowspan="1" colspan="1">71.8±10.4</td><td valign="top" align="left" rowspan="1" colspan="1">67.9±9.5</td><td valign="top" align="left" rowspan="1" colspan="1">76.3±6.3</td><td valign="top" align="left" rowspan="1" colspan="1">74.8±9.6</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">pCO<sub>2</sub></td><td valign="top" align="left" rowspan="1" colspan="1">42.0±5.3</td><td valign="top" align="left" rowspan="1" colspan="1">42.5±4.8</td><td valign="top" align="left" rowspan="1" colspan="1">41.7±3.9</td><td valign="top" align="left" rowspan="1" colspan="1">43.1±6.9</td><td valign="top" align="left" rowspan="1" colspan="1">40.4±3.1</td><td valign="top" align="left" rowspan="1" colspan="1">40.3±3.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.003</td><td valign="top" align="left" rowspan="1" colspan="1">0.004</td><td valign="top" align="left" rowspan="1" colspan="1">0.8</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HCO<sub>3</sub></td><td valign="top" align="left" rowspan="1" colspan="1">24.3±1.2</td><td valign="top" align="left" rowspan="1" colspan="1">23.6±2.0</td><td valign="top" align="left" rowspan="1" colspan="1">24.4±1.8</td><td valign="top" align="left" rowspan="1" colspan="1">24.0±1.3</td><td valign="top" align="left" rowspan="1" colspan="1">23.4±1.8</td><td valign="top" align="left" rowspan="1" colspan="1">23.9±2.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.07</td><td valign="top" align="left" rowspan="1" colspan="1">0.08</td><td valign="top" align="left" rowspan="1" colspan="1">0.10</td></tr></tbody></table><table-wrap-foot><fn id="tfn5-copd-13-617"><p><bold>Abbreviations:</bold> CRP, C-reactive protein; DLCO, diffusing lung capacity monoxide; FEV<sub>1</sub>, forced expiratory volume in 1 second; FVC, forced vital capacity; HFCWO, high-frequency chest wall oscillation; IPV, intrapulmonary percussive ventilation; MEP, maximal expiratory pressure; MIP, maximal inspiratory pressure; RV, residual volume; TLC, total lung capacity.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-copd-13-617" position="float"><label>Table 4</label><caption><p>Changes in sputum cell count</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1">Variable</th><th rowspan="2" valign="top" align="left" colspan="1">Control group</th><th rowspan="2" valign="top" align="left" colspan="1">IPV group</th><th rowspan="2" valign="top" align="left" colspan="1">HFCWO group</th><th rowspan="2" valign="top" align="left" colspan="1">Control group</th><th rowspan="2" valign="top" align="left" colspan="1">IPV group</th><th rowspan="2" valign="top" align="left" colspan="1">HFCWO group</th><th colspan="3" valign="top" align="left" rowspan="1"><italic>p</italic>-value
<hr></hr></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">IPV/control</th><th valign="top" align="left" rowspan="1" colspan="1">HFCWO/control</th><th valign="top" align="left" rowspan="1" colspan="1">IPV/HFCWO</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Total cells</td><td valign="top" align="left" rowspan="1" colspan="1">4.52±1.51</td><td valign="top" align="left" rowspan="1" colspan="1">4.83±135</td><td valign="top" align="left" rowspan="1" colspan="1">4.45±1.54</td><td valign="top" align="left" rowspan="1" colspan="1">5.26±1.25</td><td valign="top" align="left" rowspan="1" colspan="1">4.12±75</td><td valign="top" align="left" rowspan="1" colspan="1">3.98±1.08</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.15</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Neutrophils</td><td valign="top" align="left" rowspan="1" colspan="1">71±8</td><td valign="top" align="left" rowspan="1" colspan="1">72±11</td><td valign="top" align="left" rowspan="1" colspan="1">72±8</td><td valign="top" align="left" rowspan="1" colspan="1">75±8</td><td valign="top" align="left" rowspan="1" colspan="1">61±9</td><td valign="top" align="left" rowspan="1" colspan="1">64±8</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lymphocytes</td><td valign="top" align="left" rowspan="1" colspan="1">2.2±0.5</td><td valign="top" align="left" rowspan="1" colspan="1">2.3±8</td><td valign="top" align="left" rowspan="1" colspan="1">2.3±0.7</td><td valign="top" align="left" rowspan="1" colspan="1">1.9±0.4</td><td valign="top" align="left" rowspan="1" colspan="1">2.8±0.8</td><td valign="top" align="left" rowspan="1" colspan="1">2.7±0.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.001</td><td valign="top" align="left" rowspan="1" colspan="1">0.17</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Eosinophils</td><td valign="top" align="left" rowspan="1" colspan="1">2±1</td><td valign="top" align="left" rowspan="1" colspan="1">3±2</td><td valign="top" align="left" rowspan="1" colspan="1">2±1</td><td valign="top" align="left" rowspan="1" colspan="1">2±1</td><td valign="top" align="left" rowspan="1" colspan="1">3±1</td><td valign="top" align="left" rowspan="1" colspan="1">3±1</td><td valign="top" align="left" rowspan="1" colspan="1">0.07</td><td valign="top" align="left" rowspan="1" colspan="1">0.06</td><td valign="top" align="left" rowspan="1" colspan="1">0.19</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Macrophages</td><td valign="top" align="left" rowspan="1" colspan="1">16±7</td><td valign="top" align="left" rowspan="1" colspan="1">15±12</td><td valign="top" align="left" rowspan="1" colspan="1">16±10</td><td valign="top" align="left" rowspan="1" colspan="1">21±6</td><td valign="top" align="left" rowspan="1" colspan="1">4±5</td><td valign="top" align="left" rowspan="1" colspan="1">16±5</td><td valign="top" align="left" rowspan="1" colspan="1">0.01</td><td valign="top" align="left" rowspan="1" colspan="1">0.01</td><td valign="top" align="left" rowspan="1" colspan="1">0.11</td></tr></tbody></table><table-wrap-foot><fn id="tfn6-copd-13-617"><p><bold>Notes:</bold> Total cells count 10<sup>6</sup>/g. Neutrophils, lymphocytes, eosynophils, and macrophages are expressed as percentage ± SD.</p></fn><fn id="tfn7-copd-13-617"><p><bold>Abbreviations:</bold> HFCWO, high-frequency chest wall oscillation; IPV, intrapulmonary percussive ventilation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-copd-13-617" position="float"><label>Table 5</label><caption><p>Ratings and ranking of patient preferences for airway clearance techniques</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variable</th><th valign="top" align="left" rowspan="1" colspan="1">IPV group</th><th valign="top" align="left" rowspan="1" colspan="1">HFCWO group</th><th valign="top" align="left" rowspan="1" colspan="1"><italic>p</italic>-value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Comfort</td><td valign="top" align="left" rowspan="1" colspan="1">3.42±0.44</td><td valign="top" align="left" rowspan="1" colspan="1">3.47±0.53</td><td valign="top" align="left" rowspan="1" colspan="1">0.810</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Efficacy</td><td valign="top" align="left" rowspan="1" colspan="1">2.67±0.94</td><td valign="top" align="left" rowspan="1" colspan="1">2.91±1.08</td><td valign="top" align="left" rowspan="1" colspan="1">0.954</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ease of use</td><td valign="top" align="left" rowspan="1" colspan="1">3.04±0.93</td><td valign="top" align="left" rowspan="1" colspan="1">2.64±0.62</td><td valign="top" align="left" rowspan="1" colspan="1">0.072</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Convenience</td><td valign="top" align="left" rowspan="1" colspan="1">3.21±0.33</td><td valign="top" align="left" rowspan="1" colspan="1">2.91±0.16</td><td valign="top" align="left" rowspan="1" colspan="1">0.754</td></tr></tbody></table><table-wrap-foot><fn id="tfn8-copd-13-617"><p><bold>Note:</bold> Values are expressed as mean ± SD.</p></fn><fn id="tfn9-copd-13-617"><p><bold>Abbreviations:</bold> HFCWO, high-frequency chest wall oscillation; IPV, intrapulmonary percussive ventilation.</p></fn></table-wrap-foot></table-wrap></floats-group></article>